<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60226</article-id><article-id pub-id-type="doi">10.7554/eLife.60226</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Glutamine metabolism modulates azole susceptibility in <italic>Trypanosoma cruzi</italic> amastigotes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-193978"><name><surname>Dumoulin</surname><given-names>Peter C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4377-0964</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-193979"><name><surname>Vollrath</surname><given-names>Joshua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6673-3050</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214173"><name><surname>Tomko</surname><given-names>Sheena Shah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-193980"><name><surname>Wang</surname><given-names>Jennifer X</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4567"><name><surname>Burleigh</surname><given-names>Barbara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3642-7247</contrib-id><email>bburleig@hsph.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Institute for Pharmacy and Molecular Biotechnology, Heidelberg University</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution>Harvard Center for Mass Spectrometry, Harvard University</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>McConville</surname><given-names>Malcolm J</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution>University of Geneva</institution><country>Switzerland</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e60226</elocation-id><history><date date-type="received" iso-8601-date="2020-06-19"><day>19</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-17"><day>17</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Dumoulin et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Dumoulin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60226-v1.pdf"/><abstract><p>The mechanisms underlying resistance of the Chagas disease parasite, <italic>Trypanosoma cruzi,</italic> to current therapies are not well understood, including the role of metabolic heterogeneity. We found that limiting exogenous glutamine protects actively dividing amastigotes from ergosterol biosynthesis inhibitors (azoles), independent of parasite growth rate. The antiparasitic properties of azoles are derived from inhibition of lanosterol 14α-demethylase (CYP51) in the endogenous sterol synthesis pathway. We find that carbons from <sup>13</sup>C-glutamine feed into amastigote sterols and into metabolic intermediates that accumulate upon CYP51 inhibition. Incorporation of <sup>13</sup>C-glutamine into endogenously synthesized sterols is increased with BPTES treatment, an inhibitor of host glutamine metabolism that sensitizes amastigotes to azoles. Similarly, amastigotes are re-sensitized to azoles following addition of metabolites upstream of CYP51, raising the possibility that flux through the sterol synthesis pathway is a determinant of sensitivity to azoles and highlighting the potential role for metabolic heterogeneity in recalcitrant <italic>T. cruzi</italic> infection.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Trypanosoma cruzi</kwd><kwd>metabolism</kwd><kwd>drug resistance</kwd><kwd>sterol biosynthesis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AI146815</award-id><principal-award-recipient><name><surname>Burleigh</surname><given-names>Barbara</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19POST34380209</award-id><principal-award-recipient><name><surname>Dumoulin</surname><given-names>Peter C</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008548</institution-id><institution>Harvard T.H. Chan School of Public Health</institution></institution-wrap></funding-source><award-id>McLennan Family Challenge Grant Program</award-id><principal-award-recipient><name><surname>Burleigh</surname><given-names>Barbara</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001655</institution-id><institution>Deutscher Akademischer Austauschdienst</institution></institution-wrap></funding-source><award-id>PROMOS</award-id><principal-award-recipient><name><surname>Vollrath</surname><given-names>Joshua</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>Trypanosoma cruzi</italic> intracellular amastigotes exhibit rapid resistance to azoles, independent of genetic selection, which is dependent on metabolic state and mechanistically distinct from latency.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The goal for treatment of infectious diseases caused by pathogenic bacteria or parasites is to eliminate the pathogenic microorganism from the infected host. Pathogens that persist following treatment with an antimicrobial agent may harbor genetic mutations that give rise to resistant populations. Alternatively, the pathogen may be able to achieve a dormant, non-replicative state that becomes refractory to the treatment. A third, less explored option, is the impact of metabolic and environmental heterogeneity on the efficacy of a given antimicrobial agent (<xref ref-type="bibr" rid="bib75">Yang et al., 2017</xref>). Factors such as pathogen respiration (<xref ref-type="bibr" rid="bib36">Lobritz et al., 2015</xref>), ATP levels (<xref ref-type="bibr" rid="bib9">Conlon et al., 2016</xref>), and buildup of metabolic intermediates (<xref ref-type="bibr" rid="bib15">Dumont et al., 2019</xref>) as well as environmental stressors such as the host immune response (<xref ref-type="bibr" rid="bib57">Rowe et al., 2020</xref>) can modulate antibiotic efficacy. Recent work has shown that when the metabolic state and growth rate of microbes are disentangled, the factor that correlates with antibiotic efficacy is the microbial metabolic state (<xref ref-type="bibr" rid="bib37">Lopatkin et al., 2019</xref>). Similarly, standard in vitro inhibitory activity of a candidate compound can be confounded by altered pathogen metabolism due to growth media composition (<xref ref-type="bibr" rid="bib24">Hicks et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Pethe et al., 2010</xref>) and consequently an understanding of these interactions can potentiate treatment (<xref ref-type="bibr" rid="bib71">Vestergaard et al., 2017</xref>). These complex interactions are best understood in cases of bacterial pathogenesis, but recently, similar trends are apparent in eukaryotic pathogens (<xref ref-type="bibr" rid="bib15">Dumont et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">McLean and Jacobs-Lorena, 2017</xref>; <xref ref-type="bibr" rid="bib48">Murithi et al., 2020</xref>).</p><p>A group of single-celled protozoan pathogens with significant global disease burden exhibit metabolic and growth flexibility (<xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>; <xref ref-type="bibr" rid="bib40">McConville et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Saunders et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Shah-Simpson et al., 2017</xref>) suggesting the potential for interactions with drug efficacy. The kinetoplastid protozoan parasite <italic>Trypanosoma cruzi</italic> is the causative agent of Chagas disease and infects approximately 6 million individuals (<xref ref-type="bibr" rid="bib73">WHO, 2015</xref>) resulting in substantial morbidity (<xref ref-type="bibr" rid="bib5">Bern, 2015</xref>), economic burden (<xref ref-type="bibr" rid="bib32">Lee et al., 2013</xref>) and an estimated 10,000 deaths annually (<xref ref-type="bibr" rid="bib64">Stanaway and Roth, 2015</xref>). Parasite transmission is most common through the triatomine insect vector but also occurs congenitally, orally and by transfusion or transplantation (<xref ref-type="bibr" rid="bib4">Bern et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Rassi et al., 2010</xref>). Current therapies include treatment with benznidazole or nifurtimox and include undesirable characteristics such as prolonged treatment and severe adverse events (<xref ref-type="bibr" rid="bib8">Castro and Diaz de Toranzo, 1988</xref>; <xref ref-type="bibr" rid="bib53">Pinazo et al., 2010</xref>; <xref ref-type="bibr" rid="bib72">Viotti et al., 2009</xref>). During the chronic stages of the disease, the elimination of parasitemia (<xref ref-type="bibr" rid="bib47">Murcia et al., 2010</xref>) and the clinical benefit of these therapies (<xref ref-type="bibr" rid="bib44">Morillo et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Urbina and Docampo, 2003</xref>) are uncertain. Since the continued presence of the parasite is the main driver of disease (<xref ref-type="bibr" rid="bib26">Jones et al., 1993</xref>; <xref ref-type="bibr" rid="bib66">Tarleton et al., 1997</xref>; <xref ref-type="bibr" rid="bib77">Zhang and Tarleton, 1999</xref>) a central goal for new therapies is the ability to induce sterile cure.</p><p>Azole antifungal medications that target the production of endogenous sterols were promising pre-clinical candidates for Chagas disease (<xref ref-type="bibr" rid="bib12">Docampo et al., 1981</xref>; <xref ref-type="bibr" rid="bib13">Docampo and Schmuñis, 1997</xref>; <xref ref-type="bibr" rid="bib33">Lepesheva et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Urbina, 1997</xref>) due to the presence of ergostane-type sterols in <italic>T. cruzi</italic> and an already establish tolerability and safety profile in humans (<xref ref-type="bibr" rid="bib78">Zonios and Bennett, 2008</xref>). In clinical trials, azole monotherapy resulted in parasite suppression during treatment that was not sustained following cessation of therapy (<xref ref-type="bibr" rid="bib43">Molina et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Morillo et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Torrico et al., 2018</xref>) suggesting that parasites are sensitive to therapy even in the absence of radical cure. The inability of azoles to provide sterile cure in vivo does not appear to be due to an inferior pharmacokinetic profile or high plasma binding and suggests an additional unexplored factor may influences parasite susceptibility to these compounds (<xref ref-type="bibr" rid="bib28">Khare et al., 2015a</xref>). Given the ability of intracellular <italic>T. cruzi</italic> amastigotes to adapt to their immediate metabolic environment (<xref ref-type="bibr" rid="bib7">Caradonna et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>; <xref ref-type="bibr" rid="bib61">Shah-Simpson et al., 2017</xref>), we sought to determine the extent to which plasticity influences parasite susceptibility to ergosterol biosynthesis inhibitors. Here, we show that glutamine metabolism modulates the ability of azoles to eliminate intracellular <italic>T. cruzi</italic> amastigotes, independent of growth rate.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Exogenous glutamine levels modulate sensitivity of intracellular <italic>T. cruzi</italic> amastigotes to lanosterol-14α-demethylase inhibitors</title><p>The mechanisms underlying recalcitrant <italic>T. cruzi</italic> infection are not well understood. The spontaneous emergence of non-replicative ‘latent’ <italic>T. cruzi</italic> forms (<xref ref-type="bibr" rid="bib58">Sánchez-Valdéz et al., 2018</xref>) has been put forward as a possible explanation for the failure to achieve parasitological cure following drug treatment of chronic Chagas patients. However, the potential for metabolic heterogeneity to modulate <italic>T. cruzi</italic> susceptibility to trypanocidal drugs has not been investigated. To begin to address this prospect, we sought to determine if variable growth conditions known to modulate the proliferative activity of intracellular <italic>T. cruzi</italic> amastigotes (<xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>) impact the susceptibility of <italic>T. cruzi</italic> amastigotes to trypanocidal drugs. Dose-response curves for inhibition of intracellular amastigote growth were generated for benznidazole, the first-line therapy for Chagas disease (<xref ref-type="bibr" rid="bib3">Bern et al., 2007</xref>) and ketoconazole, an azole inhibitor of trypanosome sterol synthesis (<xref ref-type="bibr" rid="bib33">Lepesheva et al., 2011</xref>), as outlined (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Shown are the dose-response data for drug-treated cultures in medium with and without supplemental glucose or glutamine. These nutrients were included in the analysis based on knowledge that <italic>T. cruzi</italic> amastigotes metabolize exogenously supplied glucose and glutamine (<xref ref-type="bibr" rid="bib61">Shah-Simpson et al., 2017</xref>) and that restriction of either carbon source slows amastigote replication without causing lethality (<xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>). Additionally, the primary neonatal human dermal fibroblasts (NHDF) used as host cells for parasite infection are tolerant of nutrient restriction (<xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>). Here, we find that the dose-response for benznidazole is not altered by these changes in the growth medium (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Similarly, intracellular amastigotes exposed to ketoconazole in complete medium, or medium lacking glucose, exhibited the full range of sensitivity to ketoconazole (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In contrast, inhibition of intracellular amastigote growth with increasing ketoconazole concentration was diminished when <italic>T. cruzi</italic>-infected monolayers were maintained in the absence of supplemental glutamine (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Analogous results were obtained with other azole inhibitors of lanosterol-14α-demethylase (CYP51), itraconazole, ravuconazole, and posaconazole (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), drugs that failed to deliver sterile cure in the clinic (<xref ref-type="bibr" rid="bib43">Molina et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Torrico et al., 2018</xref>) and in animal models (<xref ref-type="bibr" rid="bib28">Khare et al., 2015a</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>A lack of supplemental glutamine in growth medium protects intracellular <italic>T. cruzi</italic> amastigotes from the cytocidal effects of ketoconazole.</title><p>(<bold>A</bold>) Dose response curves at 66 hpi of benznidazole and (<bold>B</bold>) ketoconazole treatment, in the indicated media compositions, normalized to the largest mean in each treatment group. Mean (symbols) and standard deviation shown (n = 4). (<bold>C</bold>) Microscopic counts at 66 hpi and (<bold>D</bold>) 90 hpi of the number of amastigotes per infected host cell (n = 40), medians indicated. Cartoons at top of graph indicate conditions where extracellular trypomastigotes are visible in the culture supernatant. (<bold>E</bold>) Growth media was replaced and extracellular trypomastigotes were counted every 24 hr beginning at 90 hpi (n = 2). (<bold>F</bold>) Detection of clonal outgrowth 14 days after the indicated treatments, normalized to DMSO (vehicle) treatment. Mean and standard deviation shown, circles indicates values of two independent experiments with 28 wells used per treatment within an experiment. (<bold>G</bold>) Dose response curves of glutamine in the presence of DMSO or (<bold>H</bold>) ketoconazole (5 nM). Mean and standard deviation shown (n = 3). Grey shading indicates in panel I shows the physiological range found in human plasma (800–300 uM) (<xref ref-type="bibr" rid="bib11">Cruzat et al., 2018</xref>). Statistical comparisons between medians (<bold>C,D</bold>) were performed using a Kruskal-Wallis test with Dunn’s multiple comparisons test (****p&lt;0.0001, ns = not significant). Comparisons of means from outgrowth (<bold>F</bold>) was performed using a two-way ANOVA with Dunnett’s multiple comparisons test (*p&lt;0.05, **p&lt;0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Experimental schematic for in vitro infection and readouts.</title><p>Trypomastigotes (Tula-βgal) are incubated with mammalian host cells for 2 hr to allow invasion. Remaining extracellular parasites are subsequently removed by thorough rinsing of monolayers. Internalized parasites undergo differentiation into mature amastigotes and any treatments or media adjustments are initiated at 18 hpi prior to the first amastigote division. At indicated time points post-infection (e.g. 42–90 hpi), infected cultures have one of several fates depending on the experiment, as illustrated and described in detail in the Materials and methods.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Sensitivity to additional azole drugs is modulated by glutamine.</title><p>(<bold>A</bold>) Dose response curves of itraconazole, (<bold>B</bold>) ravuconazole, and (<bold>C</bold>) posaconazole treatment measured at 66 hpi. Treatment including media compositions are indicated and growth is normalized to the largest mean in each data set. Mean (symbols) and standard deviation show (n = 4).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Removal of supplemental glutamine but not glucose maintains the proportion of infected host cells in the presence of azoles.</title><p>The number of infected cells per field (n = 20) at (<bold>A</bold>) 66 hpi and (<bold>B</bold>) 90 hpi, mean and standard deviations shown. Comparisons of means (<bold>D,F</bold>) were performed using a one-way ANOVA and Bonferroni’s multiple comparisons test (****p&lt;0.0001, ns = not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Proline or histidine supplementation do not sensitize amastigotes to ketoconazole in the absence of glutamine.</title><p>Dose response curves of (<bold>A</bold>) proline and (<bold>B</bold>) histidine in the absence of supplemental glutamine (n = 3).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Slowed amastigote growth, antioxidants, or hypoxia does not prevent the cidal effects of ketoconazole.</title><p>(<bold>A</bold>) Microscopic counts of amastigotes per host cell (n = 40) and (<bold>B</bold>) proportion of infected cells (n = 20) at 66 hpi following treatment at 18 hpi with ketoconazole (5 nM) and/or GNF7686 (150 nM) under the indicated conditions. (<bold>C</bold>) Microscopic counts of amastigotes per host cell (n = 40) and (<bold>D</bold>) proportion of infected cells (n = 20) at 90 hpi following treatment at 18 hpi with ketoconazole (5 nM) and/or GNF7686 (150 nM) under the indicated conditions. Statistical comparisons between medians (<bold>A,C</bold>) were performed using a Kruskal-Wallis test with Dunn’s multiple comparisons test (****p&lt;0.0001, **p&lt;0.01, ns = not significant). Comparisons of means (<bold>B,D</bold>) were performed using a one-way ANOVA and Bonferroni’s multiple comparisons test (****p&lt;0.0001, *p&lt;0.05, ns = not significant). (<bold>E</bold>) Normalized dose response of N-acetylcysteine and (<bold>F</bold>) glutathione measured at 66 hpi in the indicated treatment conditions. Mean and standard deviations are show (n = 2). (<bold>G</bold>) Microscopic counts of the number of amastigotes per infected host cell, mean indicated, (n = 40) and (<bold>H</bold>) the number of infected cells per 20 fields, mean and standard deviation shown (n = 3). Growth in complete medium under normoxia (20% atmospheric oxygen) or hypoxia (1.3% oxygen) and ketoconazole (5 nM) where indicated. (<bold>I</bold>) Western blot of uninfected whole host cell lysate. Hif1α is induced under hypoxia and in the presence of DMOG (0.8 mM for 6 hr) as a positive control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig1-figsupp5-v1.tif"/></fig></fig-group><p>Microscopic analysis of fixed parasite-infected fibroblast monolayers confirmed these findings (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>). For these experiments, the infecting dose of <italic>T. cruzi</italic> trypomastigotes was titrated to achieve an average of one parasite in each infected cell prior to the introduction of a test condition (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Differences in parasite numbers per infected cell or the number of host cells that retain intracellular parasites at later time points provides a reliable metric for growth inhibition and parasite death, respectively, which cannot be resolved using the β-Glo assay (e.g. <xref ref-type="fig" rid="fig1">Figure 1A,B</xref>) a rapid higher throughput assay that reports relative parasite abundance (<xref ref-type="bibr" rid="bib17">Dumoulin and Burleigh, 2020</xref>; <xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>). Microscopic counts reveal that growth of intracellular <italic>T. cruzi</italic> amastigotes exposed to 5 nM ketoconazole (&gt;IC<sub>99</sub>) for 48 hr (66 hpi) in complete medium or medium without glucose was significantly impaired (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) as expected and with significant loss in the proportion of infected cells (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) suggestive of parasite death. Under conditions of glutamine restriction, intracellular <italic>T. cruzi</italic> amastigotes survived ketoconazole exposure (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and continued to replicate as evidenced by the greater number of amastigotes per infected cell at 90 hpi (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) with no reduction in the proportion of infected cells under these conditions at this time point (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). The detection of extracellular trypomastigotes in the supernatants of untreated cultures and in those treated with ketoconazole in the absence of glutamine at 90 hpi (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; symbols), further demonstrates that these ketoconazole-treated amastigotes are competent to complete the intracellular cycle in mammalian host cells and to produce trypomastigotes. As expected given the slower growth of amastigotes in fibroblasts cultured without glutamine and exposed to ketoconazole, the production of trypomastigotes is delayed as compared to untreated controls (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>To evaluate the longer-term impact of ketoconazole exposure on intracellular <italic>T. cruzi</italic> amastigotes cultured in the absence of supplemental glutamine, a clonal outgrowth assay was utilized to quantitatively measure parasite rebound following treatment (<xref ref-type="bibr" rid="bib17">Dumoulin and Burleigh, 2020</xref>; <xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>). Detection of outgrowth (&gt;14 days), requires surviving parasites to successfully complete several lytic cycles and therefore this assay distinguishes cytostatic from cidal effects of a test compound. Exposure of intracellular amastigotes to increasing concentrations of ketoconazole in complete medium (from 18 hpi - 66 hpi) results in a proportional decrease in clonal outgrowth (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), consistent with irreversible cytotoxicity incurred by exposure to ketoconazole (<xref ref-type="bibr" rid="bib20">Goad et al., 1989</xref>). In contrast, no evidence of killing was seen when supplemental glutamine was restricted during the period of ketoconazole exposure as clonal outgrowth was comparable to vehicle-treated controls under these conditions (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Extending the ketoconazole exposure time to 72 hr did not alter this outcome (not shown). Combined, these results confirm that intracellular <italic>T. cruzi</italic> amastigotes are protected from the lethal effects of ketoconazole when supplemental glutamine levels are restricted. Not only do the parasites survive, but they continue to replicate in the presence of 5 nM ketoconazole, which is normally lethal within the time frame of exposure. Importantly, protection occurs at a population level, as opposed to selection of a minor amastigote sub-population that is intrinsically refractory to the drug or in a latent, non-replicative state.</p></sec><sec id="s2-2"><title>Glutamine supplementation sensitizes intracellular <italic>T. cruzi</italic> amastigotes to ketoconazole in a dose-dependent manner</title><p>Intracellular <italic>T. cruzi</italic> amastigotes succumb to the toxic effects of azoles when glutamine (2 mM) is present in the in vitro growth medium (<xref ref-type="fig" rid="fig1">Figure 1A–F</xref>). Given that standard glutamine concentrations in culture medium (1–2 mM) are significantly higher than the physiologic range of human plasma (800–300 μM) (<xref ref-type="bibr" rid="bib11">Cruzat et al., 2018</xref>), supplemental glutamine was added back to glutamine-free DMSO and ketoconazole-treated cultures (<xref ref-type="fig" rid="fig1">Figure 1G,H</xref>; respectively) to determine the concentration range of exogenous glutamine that sensitizes intracellular amastigotes to ketoconazole. In the absence of drug, the intracellular parasite load increases linearly with the addition of glutamine (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), but in the presence of a fixed concentration of ketoconazole (5 nM), supplemental glutamine decreased amastigote growth in a dose-dependent manner (IC<sub>50</sub> of 133.4 µM for glutamine; <xref ref-type="fig" rid="fig1">Figure 1H</xref>). Addition of amino acids known to be metabolized by the epimastigote stage (proline or histidine)(<xref ref-type="bibr" rid="bib2">Barisón et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Sylvester and Krassner, 1976</xref>), but not present in the base mammalian growth medium, failed to sensitize amastigotes to ketoconazole or impact parasite growth in the absence of glutamine (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). These results point to glutamine metabolism or a glutamine sensitive process in the parasite, host cell or both, as a key factor in the susceptibility of intracellular <italic>T. cruzi</italic> amastigotes to azole drugs.</p></sec><sec id="s2-3"><title>Slowed parasite growth does not explain glutamine-sensitive survival of ketoconazole-treated intracellular amastigotes</title><p>Since intracellular <italic>T. cruzi</italic> amastigote growth is slowed under conditions of glutamine restriction in vitro (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>), and slower growing parasites may be less susceptible to inhibitors of anabolic processes such as sterol synthesis, we cannot rule out the possibility that reduced growth rate alone might protect parasites from the lethal effects of azoles. To assess whether slowed growth is an underlying factor in the protection of intracellular amastigotes from azole-mediated death, we exploited a small molecule inhibitor of parasite cytochrome b, GNF7686 (<xref ref-type="bibr" rid="bib29">Khare et al., 2015b</xref>) that acts cytostatically to reduce amastigote replication rates in a dose-dependent manner and with no detectable interaction with glutamine (<xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref>). At early time points both glutamine restriction and GNF7686 treatment protect parasites from ketoconazole (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5A,B</xref>), but unlike the protection observed in the absence of supplemental glutamine, the slower growing GNF7686-treated parasites succumbed to ketoconazole treatment in complete medium by 90 hpi (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5C,D</xref>). Importantly, GNF7686 treatment did not interfere with survival of azole-treated amastigotes under conditions of glutamine restriction.</p><p>Other factors associated with glutamine restriction but independent of parasite growth rate may mediate protection from azoles including the generation of reactive oxygen species (ROS) due to glutamine deprivation (<xref ref-type="bibr" rid="bib39">Matés et al., 2002</xref>), cytochrome b inhibition (<xref ref-type="bibr" rid="bib14">Dröse and Brandt, 2008</xref>; <xref ref-type="bibr" rid="bib18">Fridovich, 1978</xref>) or variations in oxygen consumption which is a requirement for sterol synthesis (<xref ref-type="bibr" rid="bib50">Parks, 1978</xref>). ROS does not play a role in protection of intracellular <italic>T. cruzi</italic> amastigotes from azole-mediated cytotoxicity given that antioxidant supplementation does not alter the susceptibility of amastigotes to azoles under any of the conditions tested (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5E,F</xref>). Similar outcomes were achieved when experiments were conducted under normoxic (~20% O<sub>2</sub>) or hypoxic (1.3% O<sub>2</sub>) conditions (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5G–I</xref>). Thus, combined with the observation that restriction of supplemental glucose, another amastigote growth-limiting condition fails to protect intracellular parasites from ketoconazole (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>), our results point to dysregulated glutamine metabolism, rather than slowed parasite growth or oxidative stress, in the survival of intracellular <italic>T. cruzi</italic> amastigotes following exposure to azoles.</p></sec><sec id="s2-4"><title>Glutamine-derived carbons are incorporated into amastigote sterols</title><p>The connection between glutamine availability and amastigote sensitivity to azoles is not clear. If CYP51 inhibition by azoles results in the build-up of 14-methylated intermediates that become toxic to the parasite, then any condition that modulates metabolic flux in the direction of CYP51 has the potential to modulate this pool of intermediates. To investigate the possibility of a metabolic link between exogenous glutamine and endogenous sterol synthesis in amastigotes, metabolic <sup>13</sup>C-tracer analysis was performed. <italic>T. cruzi</italic>-infected fibroblasts were cultured in medium supplemented with universally labeled [U <sup>13</sup>C]-glutamine (2 mM) in the presence and absence of 5 nM ketoconazole. Intracellular amastigotes were isolated at 52 hpi, a time point that maximizes labeling time and minimizes parasite loss due to azole treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) under conditions that minimize contamination from host cell membranes (<xref ref-type="bibr" rid="bib19">Gazos-Lopes et al., 2017</xref>). The GC-MS chromatograms of sterols extracted from untreated amastigotes reveal several peaks with retention times between 12.4 and 13.3 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) that disappear in ketoconazole-treated parasites (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) indicating their positions up- or downstream of CYP51 in the sterol synthesis pathway (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Carbons from exogenous <sup>13</sup>C-glutamine were incorporated into sterol species downstream of CYP51 (e.g. zymosterol and isomers of ergosterol and episterol; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Consistent with reports that <italic>T. cruzi</italic> amastigotes do not generate ergosterol as a final species from endogenous sterol synthesis (<xref ref-type="bibr" rid="bib22">Gunatilleke et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Liendo et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Ottilie et al., 2017</xref>) we could not detect canonical ergosterol in this analysis, although isomers of ergosterol were present (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). <sup>13</sup>C-labeled lanosterol and eburicol, both upstream of CYP51, accumulated in azole-treated amastigotes (<xref ref-type="fig" rid="fig2">Figure 2</xref>) as expected (<xref ref-type="bibr" rid="bib22">Gunatilleke et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Ottilie et al., 2017</xref>). In addition to these sterols, host-derived cholesterol was present in all samples, independent of azole treatment and did not incorporate <sup>13</sup>C under any of the conditions examined. Notably, <sup>13</sup>C incorporation into some amastigote sterols was as high as 20–30% (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), suggesting that the contribution of exogenous glutamine to the endogenous sterol pool in <italic>T. cruz</italic>i amastigotes is significant.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Glutamine-derived carbons are incorporated into amastigote sterols and influence the buildup of lanosterol.</title><p>(<bold>A</bold>) Chromatogram from GC-MS detection of samples. Host-cell-derived cholesterol is seen at retention time 12.21, eburicol at 13.30, lanosterol at 13.04 and the internal standard at 12.98. (<bold>B</bold>) Table of detectable isolated amastigote sterol species from panel A and the percentage of natural sterols (i.e. without detectable <sup>13</sup>C). The proportion of species found with the indicated number of incorporated <sup>13</sup>C carbons are shown (e.g. 13C1, 13C2). (<bold>C</bold>) Quantification, using an internal standard, of lanosterol and (<bold>D</bold>) eburicol in isolated amastigotes (52 hpi) following treatment with ketoconazole (5 nM) at 18 hpi with or without glutamine (2 mM). Mean and standard deviation shown of independent treatments, infections and amastigote isolations (n = 2). Statistical comparisons are made using a Student’s t-test (*p&lt;0.05, ns = not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Time course establishes 52 hpi as optimal time point to harvest intracellular amastigotes following ketoconazole treatment.</title><p>Time course following treatment with ketoconazole (5 nM) in complete media. (<bold>A</bold>) Amastigotes per infected host cell (n = 40) and (<bold>B</bold>) infected cells per 20 fields are shown. Fifty-two hpi identified as maximum time of ketoconazole exposure prior to measurable loss of intracellular amastigotes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Endogenous lanosterol and eburicol but not host derived cholesterol are reliable quantifiable from isolated intracellular amastigotes.</title><p>Isolated amastigotes (52 hpi) were prepared on three independent occasions (biological) and each isolation was extracted three separate times (sterol extraction). The coefficient of variation of standard normalized area (GC-MS) was determined, means indicated. Variation in cholesterol between biological replicates prohibits reliable quantification.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig2-figsupp2-v1.tif"/></fig></fig-group><p>With the establishment of a metabolic link between glutamine and sterol biosynthesis in <italic>T. cruzi</italic> amastigotes (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>), we sought to determine the impact of glutamine restriction on amastigote sterol levels using internal standard (ISTD)-based quantification (GC-MS/ISTD). The low experimental variation in normalized lanosterol and eburicol levels (coefficient of variation &lt;0.3; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>) validates this comparative approach, and also highlights the variability in host-derived cholesterol in different biological samples (coefficient of variation &gt;0.3; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). We find that the increase in lanosterol that occurs with azole treatment compared to non-treated controls to be lower in amastigotes cultured in medium without supplemental glutamine (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), whereas eburicol levels were similar in both conditions (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>With this reasoning, we sought to determine how perturbation of host glutamine metabolism would impact amastigote sterol pools. We employed BPTES, a small molecule inhibitor of the host glutaminase (GLS1) enzyme, to block the conversion of glutamine to glutamate in the host cell (<xref ref-type="bibr" rid="bib56">Robinson et al., 2007</xref>). As <italic>T. cruzi</italic> lacks a glutaminase with discernable identity to human GLS1 and BPTES fails to inhibit glutamine-dependent respiration in amastigotes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), a process that requires the conversion of glutamine to glutamate, we expect that any effect(s) of BPTES are due to the inhibition of host GLS1 and related metabolic changes. Our results show that [U <sup>13</sup>C]-glutamine incorporation into endogenously synthesized amastigote sterols is significantly increased as compared to untreated control parasites (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This result is consistent with the idea that inhibition of host GLS1 with BPTES increases glutamine availability for intracellular amastigotes to take up, increasing the flow of carbons from glutamine into the parasite sterol pool. The increase in <sup>13</sup>C-labeling of amastigote sterols in the presence of BPTES coincides with a marked increase in the relative amounts of endogenously synthesized sterols (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), bolstering the conclusion that sterol production in intracellular <italic>T. cruzi</italic> amastigotes is influenced by glutamine availability and/or flux through the sterol synthesis pathway.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Treatment with BPTES increases incorporation of carbons from glutamine into endogenously synthesized amastigote sterols.</title><p>(<bold>A</bold>) Table of detectable isolated amastigote sterol species from and the percentage of natural sterols (i.e. without detectable <sup>13</sup>C). The proportion of species found with the indicated number of incorporated <sup>13</sup>C carbons are shown (e.g. 13C1, 13C2). (<bold>B</bold>) Normalized area (ISTD) of the indicated species without and without BPTES treatment.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>BPTES does not inhibit oxygen consumption of isolated amastigotes from glutamine and sensitizes amastigotes to ketoconazole.</title><p>(<bold>A</bold>) Measurement of the oxygen consumption rate (OCR) of isolated amastigotes when glutamine is the sole carbon source. BPTES was injected three times, increasing the BPTES concentration by 5 μM per injection for a final well concentration of 15 µM. (<bold>B</bold>) Dose response curves of glutamine in the presence of ketoconazole and at various indicated concentrations of BPTES.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Treatment with BPTES or supplementation with pathway intermediates is sufficient to re-sensitize <italic>T. cruzi </italic>amastigotes to ketoconazole in the absence of glutamine</title><p>The generation of 14-methylated sterol precursors has been implicated in the detrimental phenotypes associated with inactivation of CYP51 in other kinetoplastid protozoan parasites and in yeast (<xref ref-type="bibr" rid="bib20">Goad et al., 1989</xref>; <xref ref-type="bibr" rid="bib27">Kelly et al., 1995</xref>; <xref ref-type="bibr" rid="bib46">Mukherjee et al., 2019</xref>). If flux and/or generation of these methylated intermediate species modulates the sensitivity of <italic>T. cruzi</italic> amastigotes to azoles, we reasoned that BPTES treatment, which results in increased incorporation of carbons from glutamine into parasite sterols (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), could re-sensitize the parasites to ketoconazole under conditions of glutamine restriction. While BPTES treatment alone had no measurable effect on <italic>T. cruzi</italic> amastigote replication, parasites succumbed to ketoconazole treatment in the absence of glutamine when BPTES was present (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) suggesting that glutamine-dependent sensitization of intracellular parasites to azoles is correlated with increased flux through the sterol synthesis pathway.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Addition of metabolites re-sensitize intracellular <italic>T. cruzi</italic> amastigotes to ketoconazole in the absence of glutamine.</title><p>(<bold>A</bold>) Schematic of endogenous sterol synthesis. Dash lined arrows indicate omission of steps for simplicity. (<bold>B</bold>) Microscopic counts of amastigotes per infected cell (n = 40) at 90 hpi treated with BPTES (5 μM), (<bold>C</bold>) αKG (10 mM), (<bold>D</bold>) FPP or (<bold>E</bold>) farnesol. Statistical comparisons between medians were performed using a Kruskal-Wallis test with Dunn’s multiple comparisons test (****p&lt;0.0001, ***p&lt;0.001, *p&lt;0.05, ns = not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Addition of metabolites re-sensitize infected cultures to ketoconazole in the absence of glutamine.</title><p>(<bold>A</bold>) Microscopic counts of infected cells per field (n = 20) at 90 hpi treated with BPTES (5 μM), (<bold>B</bold>) αKG (10 mM), (<bold>C</bold>) FPP or (<bold>D</bold>) farnesol. Comparisons of means were performed using a one-way ANOVA and Bonferroni’s multiple comparisons test (****p&lt;0.0001, ns = not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60226-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Next, we sought to determine if provision of metabolites downstream of glutamine in this pathway, but upstream of CYP51 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), would have a similar effect in increasing the susceptibility of intracellular amastigotes to ketoconazole in the absence of supplemental glutamine. Similar to the results with BPTES (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), addition of a cell-permeable form of α-KG, dimethyl α-ketoglutarate (di-α-KG), to parasite-infected cells resulted in a significant reduction of intracellular amastigote growth following treatment with ketoconazole in the absence of glutamine (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). However, as compared to the results with BPTES, the effect of di-α-KG was less dramatic and may reflect conversion of di-α-KG to glutamate and then to glutamine.</p><p>Moving down the pathway, we examined the possibility that delivery of an isoprenoid precursor of sterol synthesis, farnesol pyrophosphate (FPP), or farnesol itself would have a similar impact on amastigote sensitivity to ketoconazole in the absence of glutamine. In <italic>T. cruzi,</italic> isoprenoid precursors can enter the endogenous sterol synthesis pathway (<xref ref-type="bibr" rid="bib10">Cosentino and Agüero, 2014</xref>) and in other systems, exogenous supplementation of isoprenoid precursors is sufficient to chemically rescue blockage of essential metabolic function (<xref ref-type="bibr" rid="bib76">Yeh and DeRisi, 2011</xref>). In the absence of ketoconazole, addition of farnesyl pyrophosphate (FPP) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) or farnesol (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) to the culture medium had no effect on amastigote growth. In contrast, intracellular amastigotes failed to survive ketoconazole treatment in glutamine-free medium when FPP or farnesol were present (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Although we cannot rule out the possibility that the sensitizing effects of BPTES, or exogenous di-α-KG, FPP or farnesol are due to mechanisms not directly involved with endogenous sterol synthesis, these results are consistent with the conclusion that modulation of a pathway from glutamine to sterol production in intracellular <italic>T. cruzi</italic> amastigotes has a profound impact on the ability of this parasite to survive the lethal effects of azoles. As such, our findings highlight glutamine metabolism as a process that has the potential to be manipulated to improve the efficacy of antifungal azoles against <italic>T. cruzi.</italic></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The metabolic state of a microorganism can be influenced by its immediate environment and have an impact on the efficacy of antimicrobials, independent of growth rate (<xref ref-type="bibr" rid="bib37">Lopatkin et al., 2019</xref>). For pathogenic microbes, this environment is largely dependent on the status of its host. Within a host, nutrient utilization and availability vary widely across tissues (<xref ref-type="bibr" rid="bib1">Aichler and Walch, 2015</xref>; <xref ref-type="bibr" rid="bib63">Shlomi et al., 2008</xref>). Even within a single tissue, the presence of an inflammatory response alters local metabolism (<xref ref-type="bibr" rid="bib31">Kominsky et al., 2010</xref>) and in many cases leads to intracellular nutrient restriction to control pathogen growth (<xref ref-type="bibr" rid="bib21">Grohmann et al., 2017</xref>). Pathogen growth in vitro cannot always reflect the complete spectrum of metabolic environments present in vivo and consequently can confound interpretations of standard antimicrobial assays (<xref ref-type="bibr" rid="bib24">Hicks et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Pethe et al., 2010</xref>). These considerations may be especially pertinent to <italic>T. cruzi</italic>, a parasite that in its mammalian host replicates intracellularly in diverse tissues and persists for the lifetime of the host, exposing the parasite to an immune response that suppresses parasitemia without sterile cure (<xref ref-type="bibr" rid="bib34">Lewis et al., 2015</xref>).</p><p>Recent clinical trials investigating the efficacy of azoles (CYP51 inhibitors) to eliminate <italic>T. cruzi</italic> parasitemia resulted in an initial elimination of peripheral parasitemia that, unlike benznidazole the first-line therapeutic, was not maintained after cessation of therapy (<xref ref-type="bibr" rid="bib43">Molina et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Morillo et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Torrico et al., 2018</xref>). The anti-parasitic activity of azoles without sterile cure suggests the possibility that heterogeneous environments and/or distinct populations of parasites within a single host may underlie treatment failure. We discovered that the response of intracellular <italic>T. cruzi</italic> amastigotes to azoles was significantly impacted by the concentration of supplemental glutamine in the growth medium. Rather than manifesting as a shift in traditionally measured IC<sub>50</sub>, this effect was characterized by the inability of azoles to cause radical growth reduction at all azole concentrations tested under conditions of low or no supplemental glutamine. This observation demonstrates a novel link between metabolism and drug efficacy against <italic>T. cruzi</italic> that is specific to the nature of the treatment because we find that the efficacy of benznidazole is unchanged in these conditions.</p><p>The activity of ketoconazole is derived from blockage of an anabolic process (i.e. sterol synthesis) that is potentially less active in more slowly diving parasites. Since glutamine restriction slows amastigote proliferation we investigated if slowed growth in general, rather than glutamine metabolism, explains the observed protection. We demonstrated that slowing amastigote growth using an inhibitor (GNF7686) of parasite cytochrome b delayed, but did not prevent amastigote death due to azoles. In a similar scenario, more slowly growing <italic>T. cruzi</italic> isolates have been shown to be less susceptible to azoles in a single time point growth inhibition assay, yet rapidly dividing strains can still outgrow following treatment (<xref ref-type="bibr" rid="bib38">MacLean et al., 2018</xref>). Taken together, these data show that the dynamics of azole mediated killing of replicating amastigotes is influenced by parasite growth rate, but that growth rate is insufficient to explain the protection mediated by glutamine withdrawal shown here. An alternative explanation for parasite persistence in vivo is a cessation of amastigote division. While the nature of dormancy in <italic>T. cruzi</italic> remains under investigation (<xref ref-type="bibr" rid="bib58">Sánchez-Valdéz et al., 2018</xref>), we report here a protective mechanism that allows for continued amastigote proliferation in the presence of drug at the population level. Since, slowed growth appears to induce limited tolerance to azoles but is insufficient to provide resistance; we investigated potential mechanisms to explain the protection from azoles mediated specifically by glutamine restriction.</p><p>Similar to fungal species, <italic>T. cruzi</italic> endogenously synthesizes ergostane-type sterols. As parasites replicate, the consequences of azoles that block ergostane-type sterol synthesis are two-fold: a gradual depletion of sterol end products and the buildup of 14-methylated sterol synthesis intermediates. Drug resistance to azoles observed in fungal pathogenesis is mediated by alleviating drug activity or mitigating the consequences of azole activity. These mechanisms include mutations in the target CYP51 (<xref ref-type="bibr" rid="bib25">Howard et al., 2009</xref>), drug efflux (<xref ref-type="bibr" rid="bib54">Prasad and Rawal, 2014</xref>), selection for sterol auxotrophy (<xref ref-type="bibr" rid="bib23">Hazen et al., 2005</xref>) or suppressor mutations that alter the composition of 14-methylated sterol synthesis intermediates (<xref ref-type="bibr" rid="bib27">Kelly et al., 1995</xref>). Target site or suppressor mutations cannot explain protection mediated by glutamine restriction in <italic>T. cruzi</italic> amastigotes in our study because we found that amastigotes are protected as a population, which occurs rapidly within a single lytic cycle. Under these conditions, amastigotes are not exposed to prolonged selection. Protection from azoles mediated by glutamine withdrawal is likely not due to a decrease in activity due to drug efflux, because the generation of sterols downstream of CYP51 is abolished in the absence of glutamine, demonstrating that the activity of ketoconazole is unchanged. These data demonstrate that protection may not be mediated by changes to the activity or sensitivity of CYP51 to azoles but rather changes to the consequences of CYP51 inhibition.</p><p>Inhibition of CYP51 results in a buildup of 14-methylated sterols and an absence of downstream sterols. In another kinetoplastid parasite, increased membrane fluidity and heat sensitivity are seen in <italic>Leishmania major</italic> CYP51 knockouts (<xref ref-type="bibr" rid="bib74">Xu et al., 2014</xref>) but not in knockouts of sterol methyltransferase (<xref ref-type="bibr" rid="bib46">Mukherjee et al., 2019</xref>) suggesting that the accumulation of 14-methylated sterols rather than the absence in ergosterol effects parasite viability. Similarly, 14-methylated sterols are found in <italic>T. cruzi</italic> amastigotes when treated with azoles. We found that the carbons from glutamine enter the endogenous sterol synthesis pathway in <italic>T. cruzi</italic> amastigotes and are incorporated into the 14-methylated sterol synthesis intermediates lanosterol and eburicol. The incorporation of these carbons into amastigote sterols indirectly suggests that removal of glutamine has the potential to diminish flux through the sterol synthesis pathway. Although both lanosterol and eburicol increase in the presence of ketoconazole, the relative amount of lanosterol is less when amastigotes are grown in the absence of glutamine, suggesting that increased amounts of 14-methylated sterols influence susceptibility to azoles. As we have only measured free sterols in isolated <italic>T. cruzi</italic> amastigotes, it is possible that additional sterols or their synthesis intermediates are esterified (<xref ref-type="bibr" rid="bib51">Pereira et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Taylor and Parks, 1978</xref>) or exported from the amastigote and therefore not detected using these methods. Additionally, we have not measured changes in cholesterol scavenging from the host cell by the parasite. It is still unclear if <italic>T. cruzi</italic> amastigotes balance their endogenous synthesis of sterols with exogenous scavenged cholesterol from the host and how this dynamic can alter azole mediated killing.</p><p>An increase in 14-methylated sterols directly upstream of CYP51 during azole treatment demonstrates that metabolites are still committed to this pathway even when CYP51 is inhibited. If flux through the endogenous sterol synthesis pathway is insufficiently regulated in the presence of azoles, and a buildup of 14-methylated sterols is associated with susceptibility to azoles we reasoned that altering flux into this pathway may potentiate the activity of azoles, even in the absence of glutamine. In line with this hypothesis, when BPTES is used to block the metabolism of glutamine by the host cell, we find an increase in both incorporation of glutamine-derived carbons into parasite sterols and an increase in their overall abundance. In addition to altering incorporation of glutamine into sterols, BPTES concurrently sensitizes amastigotes to ketoconazole. Since BPTES acts early in glutamine metabolism we cannot formally exclude the possibility that other glutamine fueled pathways contribute to sensitization. Additionally, the intermediate steps of glutamine metabolism into parasite sterols remain obscure since the incorporation of labeled carbons into sterols do not occur at proportions observed in other systems (<xref ref-type="bibr" rid="bib42">Metallo et al., 2012</xref>). In support of glutamine metabolism influencing amastigote sensitivity to azoles, the addition of metabolites (α-KG/farnesol/FPP) also re-sensitive amastigotes to azoles in the absence of glutamine. However, re-sensitization to ketoconazole by farnesol/FPP may be mediated through an alternative pathway (e.g. prenylation) or through direct alterations to amastigote membranes that may be compromised by a reduction in ergostane-type sterol end products and the presence of free 14-methylated sterol species. Taken together these data show that carbons derived from glutamine enter the endogenous sterol synthesis pathway in amastigotes and that changes (direct or indirect) in sterol synthesis flux may influence the buildup of 14-methylated species and azoles sensitivity.</p><p>While glutamine is the most abundant amino acid in the human body it has a wide intracellular distribution between tissues (<xref ref-type="bibr" rid="bib11">Cruzat et al., 2018</xref>) and as a result proliferating amastigotes are predicted to be exposed to a variety of glutamine levels in vivo. Standard in vitro growth media compositions contain supraphysiologic amounts of glutamine to allow for the sustained growth of rapidly dividing cells. Data from this study show that in vitro growth conditions may belie the variable efficacy of candidate anti-parasitic compounds and offer complementary approaches to better prioritize new candidates.</p><p>The novel observations presented have implications for <italic>T. cruzi</italic> antimicrobial prioritization and further evidence that the metabolic state of a microorganism is an important consideration for determining drug susceptibility. Even though the identification of new targets for antiparasitic compounds (<xref ref-type="bibr" rid="bib30">Khare et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Khare et al., 2015b</xref>) is promising, a better understanding of parasite metabolism and reasons for failure of prior candidates has the potential to aid in the prioritization of these potential therapies. In addition, the ability to modulate drug susceptibility through nutrient availability in vitro suggests that nutrient supplementation in vivo should be explored as a potential combination therapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Strain <break/>(<italic>Trypanosoma cruzi</italic>)</td><td valign="top">Tula-βgal</td><td valign="top">ATCC</td><td valign="top">PRA-330</td><td valign="top">Tulahuén LacZ clone C4: PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/8913471">8913471</ext-link></td></tr><tr><td valign="top">Cell line <break/>(<italic>Macaca mulatta</italic>)</td><td valign="top">LLC-MK2</td><td valign="top">ATCC</td><td valign="top">CCL-7</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/14449902/">14449902</ext-link>/<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/14449901/">14449901</ext-link></td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">NHDF</td><td valign="top">Lonza</td><td valign="top">CC-2509</td><td valign="top">Normal Human Neonatal Dermal Fibroblasts</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">ketoconazole</td><td valign="top">Enzo</td><td valign="top">Cat# EI107</td><td valign="top">≥99% (HPLC)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">GNF7686</td><td valign="top">Vitas-M Laboratory</td><td valign="top">Cat# STK393240</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/26186534">26186534</ext-link></td></tr><tr><td valign="top">Other</td><td valign="top">glutamine</td><td valign="top">Gibco</td><td valign="top">Cat# A2916801</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top"><sup>13</sup>C-glutamine</td><td valign="top">Cambridge Isotope Laboratories, Inc</td><td valign="top">Cat# CLM-1822</td><td valign="top">Chemical Purity 98%</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines</title><p>Tulahuén LacZ clone C4 (Tula-βgal), PRA-330 (ATCC, Manassas, Virginia) and LLC-MK<sub>2</sub>, CCL-7 (ATCC, Manassas, Virginia) cells were obtained directly from ATCC. Normal Human Neonatal Dermal Fibroblasts (NHDF; Lonza, Basel, Switzerland) were obtained directly from Lonza, catalog number CC-2509. Testing for mycoplasma contamination was performed monthly using the PlasmoTest (InvivoGen, San Diego, California) HEK-Blue-2 kit.</p></sec><sec id="s4-2"><title>Mammalian cell culture</title><p>Mammalian cells were maintained at 37°C in a 5% CO<sub>2</sub> incubator. Dulbecco’s modified Eagle medium (DMEM; HyClone, Logan, Utah) supplemented with 10% FBS (Gibco, Waltham, Massachusetts), 25 mM glucose, 2 mM L-glutamine, and 100 U/mL penicillin-streptomycin was used for propagated for uninfected cultures (DMEM-10). Unless stated otherwise, cultures infected with <italic>Trypanosoma cruzi</italic> were maintained in DMEM with 2% FBS (DMEM-2). Normal Human Neonatal Dermal Fibroblasts (NHDF; Lonza, Basel, Switzerland) were passaged prior to reaching confluence.</p></sec><sec id="s4-3"><title>Parasite maintenance</title><p>Tula-βgal, (ATCC, Manassas, Virginia) was passaged weekly in LLC-MK<sub>2</sub> (ATCC, Manassas, Virginia) cells (<xref ref-type="bibr" rid="bib6">Buckner et al., 1996</xref>). Trypomastigotes were prepared by collecting the supernatant from infected cultures and centrifuging for 10 min at 2060 x g followed by incubation at 37°C for &gt;2 hr to allow for trypomastigotes to swim from the pellet. After incubation the supernatant containing trypomastigotes was collected and washed in DMEM-2, enumerated using a Neubauer chamber and used for subsequent infections.</p></sec><sec id="s4-4"><title>Quantification of parasite load by luminescence</title><p>Tula-βgal parasite load was measured using luminescence as described previously (<xref ref-type="bibr" rid="bib7">Caradonna et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Shah-Simpson et al., 2017</xref>). One day prior to infection NHDFs were seeded in 384-well plates (Corning, Corning, New York) at a density of 1,500 cells per well and allowed to attach. Purified trypomastigotes were added at a multiplicity of infection (MOI) of 1.25 and allowed to invade for 2 hr, followed by two washes with PBS and subsequent addition of DMEM-2 without phenol red. Treatments were initiated at 18 hr post infection (hpi) to avoid any potential impacts of trypomastigote invasion and/or differentiation. At the indicated time points, growth media was removed and 10 μl Beta-Glo (Promega, Madison, Wisconsin) was added per well. Plates were incubated for &gt;30 min at room-temperature to allow the reaction to reach equilibrium and read using an EnVision plate reader (PerkinElmer, Waltham, Massachusetts). Luminescence from uninfected wells was determined for each treatment and subtracted from infected wells to account for signal not derived from parasites.</p></sec><sec id="s4-5"><title>Compound and supplement stocks</title><p>Compounds were purchased and diluted to stock concentrations: Ketoconazole (Enzo, Farmingdale, New York) 15 mM stock in DMSO, Ravuconazole (Sigma, St. Louis, Missouri) 15 mM DMSO, Itraconazole (BioVision, Milpitas, California) 15 mM DMSO, GNF7686 (Vitas-M Laboratory, Champaign, Illinois) 5 mM stock in DMSO, FPP (Sigma, St. Louis, Missouri) 2.3 mM stock in methanol, Farnesol (Sigma, St. Louis, Missouri) 100 mM in ethanol, NAC (Sigma, St. Louis, Missouri) 200 mM in DMEM base, Glutathione (Sigma, St. Louis, Missouri) 162 mM in media, benznidazole (Sigma, St. Louis Missouri) 20 mM in DMSO, BPTES (Selleckchem, Houston Texas) 20 mM in DMSO.</p></sec><sec id="s4-6"><title>Microscopy</title><p>Host cells were seeded 1 day prior to infection on coverslips (EMS, Hatfield, Pennsylvania) in 24-well plates at a density of 4 × 10<sup>4</sup> cells per well. Cells were infected for 2 hr at a MOI of 2 and subsequently washed twice with PBS followed by addition of DMEM-2. Coverslips were fixed in 1% PFA-PBS and stained in a 0.1% Triton X-100–PBS solution containing 100 ng/ml DAPI (Sigma, St. Louis, Missouri) for 5 min. After staining, coverslips were washed with PBS and mounted with ProLong Antifade (Thermo Fisher, Waltham, Massachusetts) on glass slides. Amastigotes were counted using a Nikon eclipse TE300. Amastigotes per infected host cell and the number of infected host cells per microscopic field were recorded.</p></sec><sec id="s4-7"><title>Western blot</title><p>Uninfected cells were lysed in 1 mL M-PER Mammalian Protein Extraction Reagent (Thermo Fisher, Waltham, Massachusetts) directly in culture wells and boiled for 10 min. Soluble lysate (50 μg) was loaded onto a 10% Mini-Protean TGX Gel (Bio-Rad, Hercules, CA). Proteins were transferred to a nitrocellulose membrane and blocked with a 1:1 dilution of SEA BLOCK (Thermo Fisher, Waltham, Massachusetts): PBS overnight at 4°C. The membrane was probed in blocking buffer with anti-Hif1a EPR16897 (1:1500) (Abcam, Cambridge, MA) and anti-βactin (Sigma, St. Louis, Missouri) (1:1000) for 1 hr at room temperature in hybridization tubes. After probing the membrane was washed in 1X PBS for 30 min, replacing PBS every 5 min for a total of 6 washes. Secondary antibodies, anti-mouse DyLight 680 (Cell Signaling, Dancers, MA) (1:15,000) and anti-rabbit Dylight 800 (Thermo Fisher, Waltham, Massachusetts) (1:10,000) were added and incubated for 1 hr at room temperature. The membrane was visualized using a LI-COR imaging system (LI-COR, Lincoln, NE).</p></sec><sec id="s4-8"><title>Sterol extraction</title><p>The method for extraction of sterols was based on protocols described in <xref ref-type="bibr" rid="bib62">Sharma et al., 2017</xref>. Extraction occurred in glass PYREX tubes (Corning, Corning, New York) and all solvents used were HPLC grade or higher. Lipids were first extracted three times from cell pellets using C:M (2:1, v/v) and centrifuged each time at 1800 x g for 15 min at 4°C followed by collection of the supernatant in new tubes. The supernatant was dried under a constant stream of N<sub>2</sub> and the resulting material was subjected to a Folch’s partitioning (4:2:1.5, C:M:W). The lower phase was removed, dried under N<sub>2</sub> and re-suspended in chloroform, passed over a silica 60 column and eluted with chloroform.</p></sec><sec id="s4-9"><title>GC-MS</title><p>GC/MS analysis was performed on a Thermo Scientific TRACE 1310 Gas Chromatograph equipped with a Thermo Scientific Q Exactive Orbitrap mass spectrometry system. Fifty microliters of the (BSTFA+10% TMCS)/pyridine (5/1 v/v) was added into each vial, vortexed well, and heated at 70°C for 30 min. A total of 1 µL sample was injected into a Thermo fused-silica capillary column of cross-linked TG-5SILMS (30 m x 0.25 mm x 0.25 µm). The GC conditions were as follows: inlet and transfer line temperatures, 290°C; oven temperature program, 50°C for 0 min, 24°C/min to 325°C for 5.7 min; inlet helium carrier gas flow rate, 1 mL/min; split ratio, 5. The electron impact (EI)-MS conditions were as follows: ion source temperature, 310°C; full scan m/z range, 30–750 Da; resolution, 60,000; AGC target, 1e6; maximum IT, 200 ms. Data were acquired and analyzed with Thermo TraceFinder 4.1 software package. Standards for cholesterol, ergosterol, lanosterol, episterol, and zymosterol were used for identification. Universal <sup>13</sup>C-glutamine was re-suspended to a stock concentration of 200 mM in water (Cambridge Isotope Labs, Tewksbury, Massachusetts). Prior to sterol extraction, sitosterol-d7 (Avanti Polar Lipids, Alabaster, Alabama) was added as an internal standard (ISTD) at 1.12 μg/2e7 isolated amastigotes. Thermo Fisher Scientific’s data analysis software Compound Discoverer 3.1 was used for the measurement of the enrichment of 13C-sterols, with 30 being the maximum number of exchangeable carbon atoms.</p></sec><sec id="s4-10"><title>Amastigote isolation</title><p>Infected monolayers were washed two times with PBS and cell detachment was achieved using a sterol free dissociation reagent, Accumax (Innovative Cell Technologies, San Diego, California). Cell suspensions were washed two times with PBS by centrifugation at 700 x g for 10 min at 4°C. The resulting cell pellets were lysed by passage through a 28-gauge needle or using the Miltenyi GentleMACS dissociator (M tubes, Protein_01 protocol). Lysate was passed over a PD-10 column (GE Healthcare, Chicago, Illinois) equilibrated with PBS. Eluted parasites were washed three times in PBS by centrifugation at 2300 x g at 4°C.</p></sec><sec id="s4-11"><title>Clonal outgrowth</title><p>Measurement of clonal outgrowth utilized a modified protocol from <xref ref-type="bibr" rid="bib16">Dumoulin and Burleigh, 2018</xref> to allow for detection by luminescence. Host cells were seeded in 384 well plates and 25 trypomastigotes per well were allowed to invade for 2 hr, followed by two washes with PBS to removed uninvaded trypomastigotes. Treatments were initiated at 18 hpi and wells were washed at 66 hpi twice with PBS followed by addition of DMEM-2. Cultures were allowed to grow for 14 days and subsequently measured for presence of parasites by luminescence as described previously.</p></sec><sec id="s4-12"><title>Seahorse bioenergetics profiling</title><p>Amastigotes were isolated from infected cultures and prepared as described (<xref ref-type="bibr" rid="bib60">Shah-Simpson et al., 2016</xref>). Isolated amastigotes were profiled in Krebs-Henseleit Buffer (KHB) with 2 mM glutamine as the sole carbon source and received either BPTES (5 µM) and Antimycin A (1 µM) or KHB + glutamine during the assay. BPTES was injected three times, bringing the concentration in the well from 0 µM at baseline to 5 µM after the first injection, 10 µM after the second injection, and 15 µM after the third injection. 1 µM Antimycin A (AA) was injected last to indicate how much of the oxygen consumption rate (OCR) was due to non-mitochondrial respiration vs. basal respiration. Measurements were done with 1 min of mixing, 1 min of waiting, and 2 min of measuring.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We acknowledge the ICCB-Longwood Screening Facility at Harvard Medical School for help with optimization of plate-based luminescence assays. We also thank Dr. Igor C Almeida and Dr. Lucas Pagura for help with sterol extraction protocols. This work was funded by NIH NIAID R21 AI146815-01 awarded to BAB, American Heart Association Founders Affiliate Postdoctoral fellowship 19POST34380209 awarded to PCD, a Deutscher Akademischer Austauschdienst (DAAD) Programm zur Steigerung der Mobilität von Studierenden deutscher Hochschulen (PROMOS) fellowship awarded to JV, and McLennan Family Challenge Grant Program, Harvard TH Chan School of Public Health Dean’s Fund for Scientific Advancement awarded to BAB.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-60226-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aichler</surname> <given-names>M</given-names></name><name><surname>Walch</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice</article-title><source>Laboratory Investigation</source><volume>95</volume><fpage>422</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2014.156</pub-id><pub-id pub-id-type="pmid">25621874</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barisón</surname> <given-names>MJ</given-names></name><name><surname>Damasceno</surname> <given-names>FS</given-names></name><name><surname>Mantilla</surname> <given-names>BS</given-names></name><name><surname>Silber</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The active transport of histidine and its role in ATP production in <italic>Trypanosoma cruzi</italic></article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>48</volume><fpage>437</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/s10863-016-9665-9</pub-id><pub-id pub-id-type="pmid">27222029</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bern</surname> <given-names>C</given-names></name><name><surname>Montgomery</surname> <given-names>SP</given-names></name><name><surname>Herwaldt</surname> <given-names>BL</given-names></name><name><surname>Rassi</surname> <given-names>A</given-names></name><name><surname>Marin-Neto</surname> <given-names>JA</given-names></name><name><surname>Dantas</surname> <given-names>RO</given-names></name><name><surname>Maguire</surname> <given-names>JH</given-names></name><name><surname>Acquatella</surname> <given-names>H</given-names></name><name><surname>Morillo</surname> <given-names>C</given-names></name><name><surname>Kirchhoff</surname> <given-names>LV</given-names></name><name><surname>Gilman</surname> <given-names>RH</given-names></name><name><surname>Reyes</surname> <given-names>PA</given-names></name><name><surname>Salvatella</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Evaluation and treatment of chagas disease in the united states: a systematic review</article-title><source>Jama</source><volume>298</volume><fpage>2171</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1001/jama.298.18.2171</pub-id><pub-id pub-id-type="pmid">18000201</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bern</surname> <given-names>C</given-names></name><name><surname>Kjos</surname> <given-names>S</given-names></name><name><surname>Yabsley</surname> <given-names>MJ</given-names></name><name><surname>Montgomery</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title><italic>Trypanosoma cruzi</italic> and chagas' Disease in the united states</article-title><source>Clinical Microbiology Reviews</source><volume>24</volume><fpage>655</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1128/CMR.00005-11</pub-id><pub-id pub-id-type="pmid">21976603</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bern</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chagas’ Disease</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>456</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1410150</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckner</surname> <given-names>FS</given-names></name><name><surname>Verlinde</surname> <given-names>CL</given-names></name><name><surname>La Flamme</surname> <given-names>AC</given-names></name><name><surname>Van Voorhis</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Efficient technique for screening drugs for activity against <italic>Trypanosoma cruzi</italic> using parasites expressing beta-galactosidase</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>40</volume><fpage>2592</fpage><lpage>2597</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.11.2592</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caradonna</surname> <given-names>KL</given-names></name><name><surname>Engel</surname> <given-names>JC</given-names></name><name><surname>Jacobi</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Host metabolism regulates intracellular growth of <italic>Trypanosoma cruzi</italic></article-title><source>Cell Host &amp; Microbe</source><volume>13</volume><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.11.011</pub-id><pub-id pub-id-type="pmid">23332160</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname> <given-names>JA</given-names></name><name><surname>Diaz de Toranzo</surname> <given-names>EG</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Toxic effects of nifurtimox and Benznidazole, two drugs used against american trypanosomiasis (Chagas’ disease)</article-title><source>Biomedical and Environmental Sciences : BES</source><volume>1</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1191/0960327106het653oa</pub-id><pub-id pub-id-type="pmid">3151755</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname> <given-names>BP</given-names></name><name><surname>Rowe</surname> <given-names>SE</given-names></name><name><surname>Gandt</surname> <given-names>AB</given-names></name><name><surname>Nuxoll</surname> <given-names>AS</given-names></name><name><surname>Donegan</surname> <given-names>NP</given-names></name><name><surname>Zalis</surname> <given-names>EA</given-names></name><name><surname>Clair</surname> <given-names>G</given-names></name><name><surname>Adkins</surname> <given-names>JN</given-names></name><name><surname>Cheung</surname> <given-names>AL</given-names></name><name><surname>Lewis</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persister formation in <italic>Staphylococcus aureus</italic> is associated with ATP depletion</article-title><source>Nature Microbiology</source><volume>1</volume><elocation-id>16051</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.51</pub-id><pub-id pub-id-type="pmid">27572649</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosentino</surname> <given-names>RO</given-names></name><name><surname>Agüero</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic profiling of the isoprenoid and sterol biosynthesis pathway genes of <italic>Trypanosoma cruzi</italic></article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e96762</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096762</pub-id><pub-id pub-id-type="pmid">24828104</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruzat</surname> <given-names>V</given-names></name><name><surname>Macedo Rogero</surname> <given-names>M</given-names></name><name><surname>Noel Keane</surname> <given-names>K</given-names></name><name><surname>Curi</surname> <given-names>R</given-names></name><name><surname>Newsholme</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Glutamine: metabolism and immune function, supplementation and clinical translation</article-title><source>Nutrients</source><volume>10</volume><elocation-id>1564</elocation-id><pub-id pub-id-type="doi">10.3390/nu10111564</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docampo</surname> <given-names>R</given-names></name><name><surname>Moreno</surname> <given-names>SN</given-names></name><name><surname>Turrens</surname> <given-names>JF</given-names></name><name><surname>Katzin</surname> <given-names>AM</given-names></name><name><surname>Gonzalez-Cappa</surname> <given-names>SM</given-names></name><name><surname>Stoppani</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Biochemical and ultrastructural alterations produced by miconazole and econazole in <italic>Trypanosoma cruzi</italic></article-title><source>Molecular and Biochemical Parasitology</source><volume>3</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/0166-6851(81)90047-5</pub-id><pub-id pub-id-type="pmid">6265775</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docampo</surname> <given-names>R</given-names></name><name><surname>Schmuñis</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Sterol biosynthesis inhibitors: potential chemotherapeutics against chagas disease</article-title><source>Parasitology Today</source><volume>13</volume><fpage>129</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S0169-4758(97)01021-1</pub-id><pub-id pub-id-type="pmid">15275097</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dröse</surname> <given-names>S</given-names></name><name><surname>Brandt</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>21649</fpage><lpage>21654</lpage><pub-id pub-id-type="doi">10.1074/jbc.M803236200</pub-id><pub-id pub-id-type="pmid">18522938</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname> <given-names>L</given-names></name><name><surname>Richardson</surname> <given-names>MB</given-names></name><name><surname>van der Peet</surname> <given-names>P</given-names></name><name><surname>Marapana</surname> <given-names>DS</given-names></name><name><surname>Triglia</surname> <given-names>T</given-names></name><name><surname>Dixon</surname> <given-names>MWA</given-names></name><name><surname>Cowman</surname> <given-names>AF</given-names></name><name><surname>Williams</surname> <given-names>SJ</given-names></name><name><surname>Tilley</surname> <given-names>L</given-names></name><name><surname>McConville</surname> <given-names>MJ</given-names></name><name><surname>Cobbold</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The metabolite repair enzyme phosphoglycolate phosphatase regulates central carbon metabolism and fosmidomycin sensitivity in <italic>Plasmodium falciparum</italic></article-title><source>mBio</source><volume>10</volume><elocation-id>e02060-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02060-19</pub-id><pub-id pub-id-type="pmid">31822583</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumoulin</surname> <given-names>PC</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Stress-Induced proliferation and cell cycle plasticity of intracellular <italic>Trypanosoma cruzi</italic> Amastigotes</article-title><source>mBio</source><volume>9</volume><elocation-id>e00673-18</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00673-18</pub-id><pub-id pub-id-type="pmid">29991586</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumoulin</surname> <given-names>PC</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Methods for the investigation of <italic>Trypanosoma cruzi</italic> Amastigote Proliferation in Mammalian Host Cells</article-title><source>Methods in Molecular Biology</source><volume>2116</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0294-2_32</pub-id><pub-id pub-id-type="pmid">32221941</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridovich</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>The biology of oxygen radicals</article-title><source>Science</source><volume>201</volume><fpage>875</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1126/science.210504</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazos-Lopes</surname> <given-names>F</given-names></name><name><surname>Martin</surname> <given-names>JL</given-names></name><name><surname>Dumoulin</surname> <given-names>PC</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Host triacylglycerols shape the lipidome of intracellular trypanosomes and modulate their growth</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006800</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006800</pub-id><pub-id pub-id-type="pmid">29281741</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goad</surname> <given-names>LJ</given-names></name><name><surname>Berens</surname> <given-names>RL</given-names></name><name><surname>Marr</surname> <given-names>JJ</given-names></name><name><surname>Beach</surname> <given-names>DH</given-names></name><name><surname>Holz</surname> <given-names>GG</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>The activity of ketoconazole and other azoles against <italic>Trypanosoma cruzi</italic>: biochemistry and chemotherapeutic action <italic>in vitro</italic></article-title><source>Molecular and Biochemical Parasitology</source><volume>32</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/0166-6851(89)90069-8</pub-id><pub-id pub-id-type="pmid">2494453</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grohmann</surname> <given-names>U</given-names></name><name><surname>Mondanelli</surname> <given-names>G</given-names></name><name><surname>Belladonna</surname> <given-names>ML</given-names></name><name><surname>Orabona</surname> <given-names>C</given-names></name><name><surname>Pallotta</surname> <given-names>MT</given-names></name><name><surname>Iacono</surname> <given-names>A</given-names></name><name><surname>Puccetti</surname> <given-names>P</given-names></name><name><surname>Volpi</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Amino-acid sensing and degrading pathways in immune regulation</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>35</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2017.05.004</pub-id><pub-id pub-id-type="pmid">28545736</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunatilleke</surname> <given-names>SS</given-names></name><name><surname>Calvet</surname> <given-names>CM</given-names></name><name><surname>Johnston</surname> <given-names>JB</given-names></name><name><surname>Chen</surname> <given-names>CK</given-names></name><name><surname>Erenburg</surname> <given-names>G</given-names></name><name><surname>Gut</surname> <given-names>J</given-names></name><name><surname>Engel</surname> <given-names>JC</given-names></name><name><surname>Ang</surname> <given-names>KK</given-names></name><name><surname>Mulvaney</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Arkin</surname> <given-names>MR</given-names></name><name><surname>McKerrow</surname> <given-names>JH</given-names></name><name><surname>Podust</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diverse inhibitor chemotypes targeting <italic>Trypanosoma cruzi</italic> CYP51</article-title><source>PLOS Neglected Tropical Diseases</source><volume>6</volume><elocation-id>e1736</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001736</pub-id><pub-id pub-id-type="pmid">22860142</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazen</surname> <given-names>KC</given-names></name><name><surname>Stei</surname> <given-names>J</given-names></name><name><surname>Darracott</surname> <given-names>C</given-names></name><name><surname>Breathnach</surname> <given-names>A</given-names></name><name><surname>May</surname> <given-names>J</given-names></name><name><surname>Howell</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Isolation of cholesterol-dependent <italic>candida glabrata</italic> from clinical specimens</article-title><source>Diagnostic Microbiology and Infectious Disease</source><volume>52</volume><fpage>35</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2004.12.006</pub-id><pub-id pub-id-type="pmid">15878440</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname> <given-names>ND</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Grad</surname> <given-names>YH</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Ou</surname> <given-names>X</given-names></name><name><surname>Chang</surname> <given-names>Z</given-names></name><name><surname>Xia</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>Q</given-names></name><name><surname>Fortune</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clinically prevalent mutations in <italic>Mycobacterium tuberculosis</italic> alter propionate metabolism and mediate multidrug tolerance</article-title><source>Nature Microbiology</source><volume>3</volume><fpage>1032</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0218-3</pub-id><pub-id pub-id-type="pmid">30082724</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname> <given-names>SJ</given-names></name><name><surname>Cerar</surname> <given-names>D</given-names></name><name><surname>Anderson</surname> <given-names>MJ</given-names></name><name><surname>Albarrag</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>MC</given-names></name><name><surname>Pasqualotto</surname> <given-names>AC</given-names></name><name><surname>Laverdiere</surname> <given-names>M</given-names></name><name><surname>Arendrup</surname> <given-names>MC</given-names></name><name><surname>Perlin</surname> <given-names>DS</given-names></name><name><surname>Denning</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Frequency and evolution of azole resistance in <italic>Aspergillus fumigatus</italic> associated with treatment failure</article-title><source>Emerging Infectious Diseases</source><volume>15</volume><fpage>1068</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.3201/eid1507.090043</pub-id><pub-id pub-id-type="pmid">19624922</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>EM</given-names></name><name><surname>Colley</surname> <given-names>DG</given-names></name><name><surname>Tostes</surname> <given-names>S</given-names></name><name><surname>Lopes</surname> <given-names>ER</given-names></name><name><surname>Vnencak-Jones</surname> <given-names>CL</given-names></name><name><surname>McCurley</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Amplification of a <italic>Trypanosoma</italic> cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>48</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1993.48.348</pub-id><pub-id pub-id-type="pmid">8470772</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>SL</given-names></name><name><surname>Lamb</surname> <given-names>DC</given-names></name><name><surname>Corran</surname> <given-names>AJ</given-names></name><name><surname>Baldwin</surname> <given-names>BC</given-names></name><name><surname>Kelly</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol</article-title><source>Biochemical and Biophysical Research Communications</source><volume>207</volume><fpage>910</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1995.1272</pub-id><pub-id pub-id-type="pmid">7864896</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khare</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Stinson</surname> <given-names>M</given-names></name><name><surname>Rivera</surname> <given-names>I</given-names></name><name><surname>Groessl</surname> <given-names>T</given-names></name><name><surname>Tuntland</surname> <given-names>T</given-names></name><name><surname>Yeh</surname> <given-names>V</given-names></name><name><surname>Wen</surname> <given-names>B</given-names></name><name><surname>Molteni</surname> <given-names>V</given-names></name><name><surname>Glynne</surname> <given-names>R</given-names></name><name><surname>Supek</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Antitrypanosomal treatment with benznidazole is superior to posaconazole regimens in mouse models of chagas disease</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>59</volume><fpage>6385</fpage><lpage>6394</lpage><pub-id pub-id-type="doi">10.1128/AAC.00689-15</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khare</surname> <given-names>S</given-names></name><name><surname>Roach</surname> <given-names>SL</given-names></name><name><surname>Barnes</surname> <given-names>SW</given-names></name><name><surname>Hoepfner</surname> <given-names>D</given-names></name><name><surname>Walker</surname> <given-names>JR</given-names></name><name><surname>Chatterjee</surname> <given-names>AK</given-names></name><name><surname>Neitz</surname> <given-names>RJ</given-names></name><name><surname>Arkin</surname> <given-names>MR</given-names></name><name><surname>McNamara</surname> <given-names>CW</given-names></name><name><surname>Ballard</surname> <given-names>J</given-names></name><name><surname>Lai</surname> <given-names>Y</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Molteni</surname> <given-names>V</given-names></name><name><surname>Yeh</surname> <given-names>V</given-names></name><name><surname>McKerrow</surname> <given-names>JH</given-names></name><name><surname>Glynne</surname> <given-names>RJ</given-names></name><name><surname>Supek</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Utilizing chemical genomics to identify cytochrome <italic>b</italic> as a novel drug target for chagas disease</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1005058</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005058</pub-id><pub-id pub-id-type="pmid">26186534</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khare</surname> <given-names>S</given-names></name><name><surname>Nagle</surname> <given-names>AS</given-names></name><name><surname>Biggart</surname> <given-names>A</given-names></name><name><surname>Lai</surname> <given-names>YH</given-names></name><name><surname>Liang</surname> <given-names>F</given-names></name><name><surname>Davis</surname> <given-names>LC</given-names></name><name><surname>Barnes</surname> <given-names>SW</given-names></name><name><surname>Mathison</surname> <given-names>CJ</given-names></name><name><surname>Myburgh</surname> <given-names>E</given-names></name><name><surname>Gao</surname> <given-names>MY</given-names></name><name><surname>Gillespie</surname> <given-names>JR</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Tan</surname> <given-names>JL</given-names></name><name><surname>Stinson</surname> <given-names>M</given-names></name><name><surname>Rivera</surname> <given-names>IC</given-names></name><name><surname>Ballard</surname> <given-names>J</given-names></name><name><surname>Yeh</surname> <given-names>V</given-names></name><name><surname>Groessl</surname> <given-names>T</given-names></name><name><surname>Federe</surname> <given-names>G</given-names></name><name><surname>Koh</surname> <given-names>HX</given-names></name><name><surname>Venable</surname> <given-names>JD</given-names></name><name><surname>Bursulaya</surname> <given-names>B</given-names></name><name><surname>Shapiro</surname> <given-names>M</given-names></name><name><surname>Mishra</surname> <given-names>PK</given-names></name><name><surname>Spraggon</surname> <given-names>G</given-names></name><name><surname>Brock</surname> <given-names>A</given-names></name><name><surname>Mottram</surname> <given-names>JC</given-names></name><name><surname>Buckner</surname> <given-names>FS</given-names></name><name><surname>Rao</surname> <given-names>SP</given-names></name><name><surname>Wen</surname> <given-names>BG</given-names></name><name><surname>Walker</surname> <given-names>JR</given-names></name><name><surname>Tuntland</surname> <given-names>T</given-names></name><name><surname>Molteni</surname> <given-names>V</given-names></name><name><surname>Glynne</surname> <given-names>RJ</given-names></name><name><surname>Supek</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Proteasome inhibition for treatment of leishmaniasis, chagas disease and sleeping sickness</article-title><source>Nature</source><volume>537</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature19339</pub-id><pub-id pub-id-type="pmid">27501246</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kominsky</surname> <given-names>DJ</given-names></name><name><surname>Campbell</surname> <given-names>EL</given-names></name><name><surname>Colgan</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Metabolic shifts in immunity and inflammation</article-title><source>The Journal of Immunology</source><volume>184</volume><fpage>4062</fpage><lpage>4068</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903002</pub-id><pub-id pub-id-type="pmid">20368286</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>BY</given-names></name><name><surname>Bacon</surname> <given-names>KM</given-names></name><name><surname>Bottazzi</surname> <given-names>ME</given-names></name><name><surname>Hotez</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Global economic burden of chagas disease: a computational simulation model</article-title><source>The Lancet Infectious Diseases</source><volume>13</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70002-1</pub-id><pub-id pub-id-type="pmid">23395248</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepesheva</surname> <given-names>GI</given-names></name><name><surname>Villalta</surname> <given-names>F</given-names></name><name><surname>Waterman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting <italic>Trypanosoma cruzi</italic> sterol 14α-demethylase (CYP51)</article-title><source>Advances in Parasitology</source><volume>75</volume><fpage>65</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-385863-4.00004-6</pub-id><pub-id pub-id-type="pmid">21820552</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname> <given-names>MD</given-names></name><name><surname>Francisco</surname> <given-names>AF</given-names></name><name><surname>Taylor</surname> <given-names>MC</given-names></name><name><surname>Kelly</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A new experimental model for assessing drug efficacy against <italic>Trypanosoma cruzi</italic> infection based on highly sensitive <italic>in</italic> vivo imaging</article-title><source>Journal of Biomolecular Screening</source><volume>20</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1177/1087057114552623</pub-id><pub-id pub-id-type="pmid">25296657</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liendo</surname> <given-names>A</given-names></name><name><surname>Visbal</surname> <given-names>G</given-names></name><name><surname>Piras</surname> <given-names>MM</given-names></name><name><surname>Piras</surname> <given-names>R</given-names></name><name><surname>Urbina</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Sterol composition and biosynthesis in <italic>Trypanosoma cruzi</italic> amastigotes</article-title><source>Molecular and Biochemical Parasitology</source><volume>104</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/s0166-6851(99)00129-2</pub-id><pub-id pub-id-type="pmid">10589983</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobritz</surname> <given-names>MA</given-names></name><name><surname>Belenky</surname> <given-names>P</given-names></name><name><surname>Porter</surname> <given-names>CB</given-names></name><name><surname>Gutierrez</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>JH</given-names></name><name><surname>Schwarz</surname> <given-names>EG</given-names></name><name><surname>Dwyer</surname> <given-names>DJ</given-names></name><name><surname>Khalil</surname> <given-names>AS</given-names></name><name><surname>Collins</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antibiotic efficacy is linked to bacterial cellular respiration</article-title><source>PNAS</source><volume>112</volume><fpage>8173</fpage><lpage>8180</lpage><pub-id pub-id-type="doi">10.1073/pnas.1509743112</pub-id><pub-id pub-id-type="pmid">26100898</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopatkin</surname> <given-names>AJ</given-names></name><name><surname>Stokes</surname> <given-names>JM</given-names></name><name><surname>Zheng</surname> <given-names>EJ</given-names></name><name><surname>Yang</surname> <given-names>JH</given-names></name><name><surname>Takahashi</surname> <given-names>MK</given-names></name><name><surname>You</surname> <given-names>L</given-names></name><name><surname>Collins</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial metabolic state more accurately predicts antibiotic lethality than growth rate</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>2109</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0536-0</pub-id><pub-id pub-id-type="pmid">31451773</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname> <given-names>LM</given-names></name><name><surname>Thomas</surname> <given-names>J</given-names></name><name><surname>Lewis</surname> <given-names>MD</given-names></name><name><surname>Cotillo</surname> <given-names>I</given-names></name><name><surname>Gray</surname> <given-names>DW</given-names></name><name><surname>De Rycker</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Development of <italic>Trypanosoma cruzi in vitro</italic> assays to identify compounds suitable for progression in chagas' disease drug discovery</article-title><source>PLOS Neglected Tropical Diseases</source><volume>12</volume><elocation-id>e0006612</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006612</pub-id><pub-id pub-id-type="pmid">30001347</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matés</surname> <given-names>JM</given-names></name><name><surname>Pérez-Gómez</surname> <given-names>C</given-names></name><name><surname>Núñez de Castro</surname> <given-names>I</given-names></name><name><surname>Asenjo</surname> <given-names>M</given-names></name><name><surname>Márquez</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>34</volume><fpage>439</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(01)00143-1</pub-id><pub-id pub-id-type="pmid">11906817</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConville</surname> <given-names>MJ</given-names></name><name><surname>Saunders</surname> <given-names>EC</given-names></name><name><surname>Kloehn</surname> <given-names>J</given-names></name><name><surname>Dagley</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>Leishmania</italic> carbon metabolism in the macrophage phagolysosome- feast or famine?</article-title><source>F1000Research</source><volume>4</volume><elocation-id>938</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.6724.1</pub-id><pub-id pub-id-type="pmid">26594352</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname> <given-names>KJ</given-names></name><name><surname>Jacobs-Lorena</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Plasmodium falciparum Maf1</italic> confers survival upon amino acid starvation</article-title><source>mBio</source><volume>8</volume><elocation-id>e02317-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02317-16</pub-id><pub-id pub-id-type="pmid">28351924</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metallo</surname> <given-names>CM</given-names></name><name><surname>Gameiro</surname> <given-names>PA</given-names></name><name><surname>Bell</surname> <given-names>EL</given-names></name><name><surname>Mattaini</surname> <given-names>KR</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Hiller</surname> <given-names>K</given-names></name><name><surname>Jewell</surname> <given-names>CM</given-names></name><name><surname>Johnson</surname> <given-names>ZR</given-names></name><name><surname>Irvine</surname> <given-names>DJ</given-names></name><name><surname>Guarente</surname> <given-names>L</given-names></name><name><surname>Kelleher</surname> <given-names>JK</given-names></name><name><surname>Vander Heiden</surname> <given-names>MG</given-names></name><name><surname>Iliopoulos</surname> <given-names>O</given-names></name><name><surname>Stephanopoulos</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia</article-title><source>Nature</source><volume>481</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/nature10602</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname> <given-names>I</given-names></name><name><surname>Gómez i Prat</surname> <given-names>J</given-names></name><name><surname>Salvador</surname> <given-names>F</given-names></name><name><surname>Treviño</surname> <given-names>B</given-names></name><name><surname>Sulleiro</surname> <given-names>E</given-names></name><name><surname>Serre</surname> <given-names>N</given-names></name><name><surname>Pou</surname> <given-names>D</given-names></name><name><surname>Roure</surname> <given-names>S</given-names></name><name><surname>Cabezos</surname> <given-names>J</given-names></name><name><surname>Valerio</surname> <given-names>L</given-names></name><name><surname>Blanco-Grau</surname> <given-names>A</given-names></name><name><surname>Sánchez-Montalvá</surname> <given-names>A</given-names></name><name><surname>Vidal</surname> <given-names>X</given-names></name><name><surname>Pahissa</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Randomized trial of posaconazole and benznidazole for chronic chagas' disease</article-title><source>New England Journal of Medicine</source><volume>370</volume><fpage>1899</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1313122</pub-id><pub-id pub-id-type="pmid">24827034</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morillo</surname> <given-names>CA</given-names></name><name><surname>Marin-Neto</surname> <given-names>JA</given-names></name><name><surname>Avezum</surname> <given-names>A</given-names></name><name><surname>Sosa-Estani</surname> <given-names>S</given-names></name><name><surname>Rassi</surname> <given-names>A</given-names></name><name><surname>Rosas</surname> <given-names>F</given-names></name><name><surname>Villena</surname> <given-names>E</given-names></name><name><surname>Quiroz</surname> <given-names>R</given-names></name><name><surname>Bonilla</surname> <given-names>R</given-names></name><name><surname>Britto</surname> <given-names>C</given-names></name><name><surname>Guhl</surname> <given-names>F</given-names></name><name><surname>Velazquez</surname> <given-names>E</given-names></name><name><surname>Bonilla</surname> <given-names>L</given-names></name><name><surname>Meeks</surname> <given-names>B</given-names></name><name><surname>Rao-Melacini</surname> <given-names>P</given-names></name><name><surname>Pogue</surname> <given-names>J</given-names></name><name><surname>Mattos</surname> <given-names>A</given-names></name><name><surname>Lazdins</surname> <given-names>J</given-names></name><name><surname>Rassi</surname> <given-names>A</given-names></name><name><surname>Connolly</surname> <given-names>SJ</given-names></name><name><surname>Yusuf</surname> <given-names>S</given-names></name><name><surname>Investigators</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>1295</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1507574</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morillo</surname> <given-names>CA</given-names></name><name><surname>Waskin</surname> <given-names>H</given-names></name><name><surname>Sosa-Estani</surname> <given-names>S</given-names></name><name><surname>Del Carmen Bangher</surname> <given-names>M</given-names></name><name><surname>Cuneo</surname> <given-names>C</given-names></name><name><surname>Milesi</surname> <given-names>R</given-names></name><name><surname>Mallagray</surname> <given-names>M</given-names></name><name><surname>Apt</surname> <given-names>W</given-names></name><name><surname>Beloscar</surname> <given-names>J</given-names></name><name><surname>Gascon</surname> <given-names>J</given-names></name><name><surname>Molina</surname> <given-names>I</given-names></name><name><surname>Echeverria</surname> <given-names>LE</given-names></name><name><surname>Colombo</surname> <given-names>H</given-names></name><name><surname>Perez-Molina</surname> <given-names>JA</given-names></name><name><surname>Wyss</surname> <given-names>F</given-names></name><name><surname>Meeks</surname> <given-names>B</given-names></name><name><surname>Bonilla</surname> <given-names>LR</given-names></name><name><surname>Gao</surname> <given-names>P</given-names></name><name><surname>Wei</surname> <given-names>B</given-names></name><name><surname>McCarthy</surname> <given-names>M</given-names></name><name><surname>Yusuf</surname> <given-names>S</given-names></name><collab>STOP-CHAGAS Investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Benznidazole and posaconazole in Eliminating Parasites in Asymptomatic<italic> T. Cruzi</italic> Carriers: The STOP-CHAGAS Trial</article-title><source>Journal of the American College of Cardiology</source><volume>69</volume><fpage>939</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.12.023</pub-id><pub-id pub-id-type="pmid">28231946</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Hsu</surname> <given-names>FF</given-names></name><name><surname>Patel</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sterol methyltransferase is required for optimal mitochondrial function and virulence in <italic>leishmania major</italic></article-title><source>Molecular Microbiology</source><volume>111</volume><fpage>65</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/mmi.14139</pub-id><pub-id pub-id-type="pmid">30260041</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murcia</surname> <given-names>L</given-names></name><name><surname>Carrilero</surname> <given-names>B</given-names></name><name><surname>Muñoz</surname> <given-names>MJ</given-names></name><name><surname>Iborra</surname> <given-names>MA</given-names></name><name><surname>Segovia</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Usefulness of PCR for monitoring benznidazole response in patients with chronic chagas' disease: a prospective study in a non-disease-endemic country</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>65</volume><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq201</pub-id><pub-id pub-id-type="pmid">20542903</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murithi</surname> <given-names>JM</given-names></name><name><surname>Owen</surname> <given-names>ES</given-names></name><name><surname>Istvan</surname> <given-names>ES</given-names></name><name><surname>Lee</surname> <given-names>MCS</given-names></name><name><surname>Ottilie</surname> <given-names>S</given-names></name><name><surname>Chibale</surname> <given-names>K</given-names></name><name><surname>Goldberg</surname> <given-names>DE</given-names></name><name><surname>Winzeler</surname> <given-names>EA</given-names></name><name><surname>Llinás</surname> <given-names>M</given-names></name><name><surname>Fidock</surname> <given-names>DA</given-names></name><name><surname>Vanaerschot</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery</article-title><source>Cell Chemical Biology</source><volume>27</volume><fpage>158</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.11.009</pub-id><pub-id pub-id-type="pmid">31813848</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottilie</surname> <given-names>S</given-names></name><name><surname>Goldgof</surname> <given-names>GM</given-names></name><name><surname>Calvet</surname> <given-names>CM</given-names></name><name><surname>Jennings</surname> <given-names>GK</given-names></name><name><surname>LaMonte</surname> <given-names>G</given-names></name><name><surname>Schenken</surname> <given-names>J</given-names></name><name><surname>Vigil</surname> <given-names>E</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>McCall</surname> <given-names>LI</given-names></name><name><surname>Lopes</surname> <given-names>ES</given-names></name><name><surname>Gunawan</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Siqueira-Neto</surname> <given-names>JL</given-names></name><name><surname>McKerrow</surname> <given-names>JH</given-names></name><name><surname>Amaro</surname> <given-names>RE</given-names></name><name><surname>Podust</surname> <given-names>LM</given-names></name><name><surname>Durrant</surname> <given-names>JD</given-names></name><name><surname>Winzeler</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rapid chagas disease drug target discovery using directed evolution in Drug-Sensitive yeast</article-title><source>ACS Chemical Biology</source><volume>12</volume><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b01037</pub-id><pub-id pub-id-type="pmid">27977118</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Metabolism of sterols in yeast</article-title><source>CRC Critical Reviews in Microbiology</source><volume>6</volume><fpage>301</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.3109/10408417809090625</pub-id><pub-id pub-id-type="pmid">365459</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname> <given-names>MG</given-names></name><name><surname>Visbal</surname> <given-names>G</given-names></name><name><surname>Costa</surname> <given-names>TFR</given-names></name><name><surname>Frases</surname> <given-names>S</given-names></name><name><surname>de Souza</surname> <given-names>W</given-names></name><name><surname>Atella</surname> <given-names>G</given-names></name><name><surname>Cunha-E-Silva</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Trypanosoma cruzi</italic> epimastigotes store cholesteryl esters in lipid droplets after cholesterol endocytosis</article-title><source>Molecular and Biochemical Parasitology</source><volume>224</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2018.07.004</pub-id><pub-id pub-id-type="pmid">30016698</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pethe</surname> <given-names>K</given-names></name><name><surname>Sequeira</surname> <given-names>PC</given-names></name><name><surname>Agarwalla</surname> <given-names>S</given-names></name><name><surname>Rhee</surname> <given-names>K</given-names></name><name><surname>Kuhen</surname> <given-names>K</given-names></name><name><surname>Phong</surname> <given-names>WY</given-names></name><name><surname>Patel</surname> <given-names>V</given-names></name><name><surname>Beer</surname> <given-names>D</given-names></name><name><surname>Walker</surname> <given-names>JR</given-names></name><name><surname>Duraiswamy</surname> <given-names>J</given-names></name><name><surname>Jiricek</surname> <given-names>J</given-names></name><name><surname>Keller</surname> <given-names>TH</given-names></name><name><surname>Chatterjee</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>MP</given-names></name><name><surname>Ujjini</surname> <given-names>M</given-names></name><name><surname>Rao</surname> <given-names>SP</given-names></name><name><surname>Camacho</surname> <given-names>L</given-names></name><name><surname>Bifani</surname> <given-names>P</given-names></name><name><surname>Mak</surname> <given-names>PA</given-names></name><name><surname>Ma</surname> <given-names>I</given-names></name><name><surname>Barnes</surname> <given-names>SW</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Plouffe</surname> <given-names>D</given-names></name><name><surname>Thayalan</surname> <given-names>P</given-names></name><name><surname>Ng</surname> <given-names>SH</given-names></name><name><surname>Au</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>BH</given-names></name><name><surname>Tan</surname> <given-names>BH</given-names></name><name><surname>Ravindran</surname> <given-names>S</given-names></name><name><surname>Nanjundappa</surname> <given-names>M</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Goh</surname> <given-names>A</given-names></name><name><surname>Lakshminarayana</surname> <given-names>SB</given-names></name><name><surname>Shoen</surname> <given-names>C</given-names></name><name><surname>Cynamon</surname> <given-names>M</given-names></name><name><surname>Kreiswirth</surname> <given-names>B</given-names></name><name><surname>Dartois</surname> <given-names>V</given-names></name><name><surname>Peters</surname> <given-names>EC</given-names></name><name><surname>Glynne</surname> <given-names>R</given-names></name><name><surname>Brenner</surname> <given-names>S</given-names></name><name><surname>Dick</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A chemical genetic screen in <italic>Mycobacterium tuberculosis</italic> identifies carbon-source-dependent growth inhibitors devoid of <italic>in vivo</italic> efficacy</article-title><source>Nature Communications</source><volume>1</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms1060</pub-id><pub-id pub-id-type="pmid">20975714</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinazo</surname> <given-names>M</given-names></name><name><surname>Muñoz</surname> <given-names>J</given-names></name><name><surname>Posada</surname> <given-names>E</given-names></name><name><surname>López-Chejade</surname> <given-names>P</given-names></name><name><surname>Gállego</surname> <given-names>M</given-names></name><name><surname>Ayala</surname> <given-names>E</given-names></name><name><surname>del Cacho</surname> <given-names>E</given-names></name><name><surname>Gascon</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tolerance of benznidazole in treatment of chagas' Disease in adults</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>54</volume><fpage>4896</fpage><lpage>4899</lpage><pub-id pub-id-type="doi">10.1128/AAC.00537-10</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname> <given-names>R</given-names></name><name><surname>Rawal</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efflux pump proteins in antifungal resistance</article-title><source>Frontiers in Pharmacology</source><volume>5</volume><elocation-id>202</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00202</pub-id><pub-id pub-id-type="pmid">25221515</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassi</surname> <given-names>A</given-names></name><name><surname>Rassi</surname> <given-names>A</given-names></name><name><surname>Marin-Neto</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chagas disease</article-title><source>The Lancet</source><volume>375</volume><fpage>1388</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60061-X</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MM</given-names></name><name><surname>McBryant</surname> <given-names>SJ</given-names></name><name><surname>Tsukamoto</surname> <given-names>T</given-names></name><name><surname>Rojas</surname> <given-names>C</given-names></name><name><surname>Ferraris</surname> <given-names>DV</given-names></name><name><surname>Hamilton</surname> <given-names>SK</given-names></name><name><surname>Hansen</surname> <given-names>JC</given-names></name><name><surname>Curthoys</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)</article-title><source>Biochemical Journal</source><volume>406</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1042/BJ20070039</pub-id><pub-id pub-id-type="pmid">17581113</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname> <given-names>SE</given-names></name><name><surname>Wagner</surname> <given-names>NJ</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Beam</surname> <given-names>JE</given-names></name><name><surname>Wilkinson</surname> <given-names>AD</given-names></name><name><surname>Radlinski</surname> <given-names>LC</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Miao</surname> <given-names>EA</given-names></name><name><surname>Conlon</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reactive oxygen species induce antibiotic tolerance during systemic <italic>Staphylococcus aureus</italic> infection</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0627-y</pub-id><pub-id pub-id-type="pmid">31819212</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Valdéz</surname> <given-names>FJ</given-names></name><name><surname>Padilla</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Orr</surname> <given-names>D</given-names></name><name><surname>Tarleton</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spontaneous dormancy protects <italic>Trypanosoma cruzi</italic> during extended drug exposure</article-title><source>eLife</source><volume>7</volume><elocation-id>e34039</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34039</pub-id><pub-id pub-id-type="pmid">29578409</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>EC</given-names></name><name><surname>DE Souza</surname> <given-names>DP</given-names></name><name><surname>Naderer</surname> <given-names>T</given-names></name><name><surname>Sernee</surname> <given-names>MF</given-names></name><name><surname>Ralton</surname> <given-names>JE</given-names></name><name><surname>Doyle</surname> <given-names>MA</given-names></name><name><surname>Macrae</surname> <given-names>JI</given-names></name><name><surname>Chambers</surname> <given-names>JL</given-names></name><name><surname>Heng</surname> <given-names>J</given-names></name><name><surname>Nahid</surname> <given-names>A</given-names></name><name><surname>Likic</surname> <given-names>VA</given-names></name><name><surname>McConville</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Central carbon metabolism of <italic>leishmania</italic> parasites</article-title><source>Parasitology</source><volume>137</volume><fpage>1303</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1017/S0031182010000077</pub-id><pub-id pub-id-type="pmid">20158936</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah-Simpson</surname> <given-names>S</given-names></name><name><surname>Pereira</surname> <given-names>CF</given-names></name><name><surname>Dumoulin</surname> <given-names>PC</given-names></name><name><surname>Caradonna</surname> <given-names>KL</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bioenergetic profiling of Trypanosoma cruzi life stages using seahorse extracellular flux technology</article-title><source>Molecular and Biochemical Parasitology</source><volume>208</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2016.07.001</pub-id><pub-id pub-id-type="pmid">27392747</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah-Simpson</surname> <given-names>S</given-names></name><name><surname>Lentini</surname> <given-names>G</given-names></name><name><surname>Dumoulin</surname> <given-names>PC</given-names></name><name><surname>Burleigh</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Modulation of host central carbon metabolism and <italic>in situ</italic> glucose uptake by intracellular <italic>Trypanosoma cruzi</italic> amastigotes</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006747</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006747</pub-id><pub-id pub-id-type="pmid">29176805</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>AI</given-names></name><name><surname>Olson</surname> <given-names>CL</given-names></name><name><surname>Mamede</surname> <given-names>JI</given-names></name><name><surname>Gazos-Lopes</surname> <given-names>F</given-names></name><name><surname>Epting</surname> <given-names>CL</given-names></name><name><surname>Almeida</surname> <given-names>IC</given-names></name><name><surname>Engman</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sterol targeting drugs reveal life cycle stage-specific differences in trypanosome lipid rafts</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>9105</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-08770-9</pub-id><pub-id pub-id-type="pmid">28831063</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlomi</surname> <given-names>T</given-names></name><name><surname>Cabili</surname> <given-names>MN</given-names></name><name><surname>Herrgård</surname> <given-names>MJ</given-names></name><name><surname>Palsson</surname> <given-names>BØ</given-names></name><name><surname>Ruppin</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Network-based prediction of human tissue-specific metabolism</article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1038/nbt.1487</pub-id><pub-id pub-id-type="pmid">18711341</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanaway</surname> <given-names>JD</given-names></name><name><surname>Roth</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The burden of chagas disease: estimates and challenges</article-title><source>Global Heart</source><volume>10</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.gheart.2015.06.001</pub-id><pub-id pub-id-type="pmid">26407508</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvester</surname> <given-names>D</given-names></name><name><surname>Krassner</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Proline metabolism in <italic>Trypanosoma cruzi</italic> epimastigotes</article-title><source>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</source><volume>55</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/0305-0491(76)90318-7</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarleton</surname> <given-names>RL</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Downs</surname> <given-names>MO</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>&quot;Autoimmune rejection&quot; of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue</article-title><source>PNAS</source><volume>94</volume><fpage>3932</fpage><lpage>3937</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.8.3932</pub-id><pub-id pub-id-type="pmid">9108082</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>FR</given-names></name><name><surname>Parks</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Metabolic interconversion of free sterols and steryl esters in <italic>Saccharomyces cerevisiae</italic></article-title><source>Journal of Bacteriology</source><volume>136</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1128/JB.136.2.531-537.1978</pub-id><pub-id pub-id-type="pmid">361713</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrico</surname> <given-names>F</given-names></name><name><surname>Gascon</surname> <given-names>J</given-names></name><name><surname>Ortiz</surname> <given-names>L</given-names></name><name><surname>Alonso-Vega</surname> <given-names>C</given-names></name><name><surname>Pinazo</surname> <given-names>MJ</given-names></name><name><surname>Schijman</surname> <given-names>A</given-names></name><name><surname>Almeida</surname> <given-names>IC</given-names></name><name><surname>Alves</surname> <given-names>F</given-names></name><name><surname>Strub-Wourgaft</surname> <given-names>N</given-names></name><name><surname>Ribeiro</surname> <given-names>I</given-names></name><collab>E1224 Study Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Treatment of adult chronic indeterminate chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial</article-title><source>The Lancet Infectious Diseases</source><volume>18</volume><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30538-8</pub-id><pub-id pub-id-type="pmid">29352704</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbina</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites</article-title><source>Parasitology</source><volume>114</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1017/S0031182097001194</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbina</surname> <given-names>JA</given-names></name><name><surname>Docampo</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Specific chemotherapy of chagas disease: controversies and advances</article-title><source>Trends in Parasitology</source><volume>19</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2003.09.001</pub-id><pub-id pub-id-type="pmid">14580960</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname> <given-names>M</given-names></name><name><surname>Nøhr-Meldgaard</surname> <given-names>K</given-names></name><name><surname>Bojer</surname> <given-names>MS</given-names></name><name><surname>Krogsgård Nielsen</surname> <given-names>C</given-names></name><name><surname>Meyer</surname> <given-names>RL</given-names></name><name><surname>Slavetinsky</surname> <given-names>C</given-names></name><name><surname>Peschel</surname> <given-names>A</given-names></name><name><surname>Ingmer</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inhibition of the ATP synthase eliminates the intrinsic resistance of <italic>Staphylococcus aureus</italic> towards Polymyxins</article-title><source>mBio</source><volume>8</volume><elocation-id>e01114-17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01114-17</pub-id><pub-id pub-id-type="pmid">28874470</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viotti</surname> <given-names>R</given-names></name><name><surname>Vigliano</surname> <given-names>C</given-names></name><name><surname>Lococo</surname> <given-names>B</given-names></name><name><surname>Alvarez</surname> <given-names>MG</given-names></name><name><surname>Petti</surname> <given-names>M</given-names></name><name><surname>Bertocchi</surname> <given-names>G</given-names></name><name><surname>Armenti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Side effects of benznidazole as treatment in chronic chagas disease: fears and realities</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>7</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1586/14787210.7.2.157</pub-id><pub-id pub-id-type="pmid">19254164</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Chagas disease in Latin America: an epidemiological update based on 2010 estimates</article-title><source>Releve Epidemiologique Hebdomadaire</source><volume>90</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25671846</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Hsu</surname> <given-names>FF</given-names></name><name><surname>Baykal</surname> <given-names>E</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sterol biosynthesis is required for heat resistance but not extracellular survival in leishmania</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004427</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004427</pub-id><pub-id pub-id-type="pmid">25340392</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>JH</given-names></name><name><surname>Bening</surname> <given-names>SC</given-names></name><name><surname>Collins</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antibiotic efficacy-context matters</article-title><source>Current Opinion in Microbiology</source><volume>39</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2017.09.002</pub-id><pub-id pub-id-type="pmid">29049930</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname> <given-names>E</given-names></name><name><surname>DeRisi</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage <italic>Plasmodium falciparum</italic></article-title><source>PLOS Biology</source><volume>9</volume><elocation-id>e1001138</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001138</pub-id><pub-id pub-id-type="pmid">21912516</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Tarleton</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Parasite persistence correlates with disease severity and localization in chronic chagas' disease</article-title><source>The Journal of Infectious Diseases</source><volume>180</volume><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1086/314889</pub-id><pub-id pub-id-type="pmid">10395865</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonios</surname> <given-names>DI</given-names></name><name><surname>Bennett</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Update on azole antifungals</article-title><source>Seminars in Respiratory and Critical Care Medicine</source><volume>29</volume><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1063858</pub-id><pub-id pub-id-type="pmid">18366001</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60226.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>McConville</surname><given-names>Malcolm J</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Melbourne</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>McConville</surname><given-names>Malcolm J</given-names></name><role>Reviewer</role><aff><institution>The University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Zhang</surname><given-names>Kai</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This work demonstrates how the metabolic state of the intracellular pathogen, <italic>Trypanosoma cruzi</italic> directly influences the efficacy of clinically important azole drugs. The sensitivity of intracellular parasite stages to azoles increases markedly in the presence of physiologically relevant concentrations of glutamine, independent of growth rate. Metabolic labeling and inhibitor studies show that glutamine metabolism leads to enhanced sterol synthesis with concomitant accumulation of aberrant sterols and cytotoxicity in the presence of azoles. These findings suggest that metabolic heterogeneity in pathogenic protists, as in bacteria, contribute to the failure of some drugs to achieve sterile cure.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Glutamine metabolism modulates azole susceptibility in <italic>Trypanosoma cruzi</italic>amastigotes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Malcolm J McConville as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Dominique Soldati-Favre as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Kai Zhang (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper</p><p>Summary:</p><p>In this study, Dumoulin et al. show that <italic>Trypanosoma cruzi</italic>amastigotes are sensitized to azoles, such as ketoconazole, when exposed to increasing concentrations of glutamine, but not glucose, in their intracellular niche. They present evidence that sensitization is due to increased carbon flux into ergosterol biosynthesis, rather than changes in parasite growth rate. The findings suggest that variability in external nutrient levels and metabolic reprogramming contributes to non-genetically encoded drug resistance mechanisms in these pathogens and non-sterile cure in vivo.</p><p>Essential revisions:</p><p>The reviewers appreciated the quality of the work and the broader implications of the findings. However, a number of issues were raised that should either be addressed with addition experimental evidence or suitable caveats included in the text and/or relevant data removed from the manuscript.</p><p>1) The authors provide strong evidence that glutamine restriction alleviates the build-up of toxic 14-methyl sterol intermediate induced by ketoconazole by showing that amastigotes are re-sensitized by addition of upstream metabolites of CYP51 (like FPP). However, the phenotype of the mGDH-deficient <italic>T. cruzi</italic>amastigotes does not support the hypothesis that increased glutamate flux is responsible for sensitization to ketoconazole. Specifically, one would expect that the mutant line should be more resistant to ketoconazole in the presence of glutamine, which is not observed. The authors should reconcile these results with their model. It was noted that <italic>T. cruzi</italic> may express another active GDH which could compensate for loss of the deleted GDH, or alternatively that the GDH reaction might be by-passed by transaminase reactions. Further experiments may be needed to define the role of these GDH enzymes in ketoconazole sensitivity (including testing the effect of GDH overexpression if effective inhibition of glutamate catabolism is not possible), or these data removed from the manuscript. Along the same lines, further discussion on the phenotype of the cIDH mutant (what was expected and what was observed) is warranted.</p><p>2) Further explanation of the 13C-glutamine labelling experiments is needed (Figure 3B). The major sterol isotopomers detected in the GC-MS analyses contain +1 and +2 13C-atoms. One would expect +2 or higher isotopomers (i.e. +4, +6 etc) if glutamine is used to synthesize acetyl-CoA via citrate (either by oxidative or reductive pathways). How do the authors reconcile the observed labelling of the sterols and/or have they considered whether fatty acid b-oxidation might also be contributing to elevated acetyl-CoA and sterol synthesis under glucose limiting conditions ?</p><p>3) The evidence for the accumulation of 14-methylated sterol intermediates after ketoconazole treatment is not clear (Figure 3). Specifically, the authors should address the following issues.</p><p>• Is there any verification to show amastigote purity?</p><p>• Figure 3A: the TLC shows a loss of ergosterol/ergosterol isomer after ketoconazole treatment but no accumulation of CYP51 substrates is detected. Is the loading equal?</p><p>• Figure 3B: it seems that cholesterol is the most abundance sterol species in amastigotes based on natural sterol %, but it is not consistent with Figure 3C.</p><p>• Resolution for Figure 3B-C is insufficient.</p><p>• Figure 3C: what is the most dominant peak at 12.8-13.0 in all samples? Is it lanosterol or ergosterol isomer?</p><p>4) Figure 4: while the presented data is compelling, evidence is missing that these isoprenoid precursors are indeed affecting sterol production, rather than acting via a tertiary mechanism. Such evidence should be provided, or conclusions in text tempered.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60226.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers appreciated the quality of the work and the broader implications of the findings. However, a number of issues were raised that should either be addressed with addition experimental evidence or suitable caveats included in the text and/or relevant data removed from the manuscript.</p><p>1) The authors provide strong evidence that glutamine restriction alleviates the build-up of toxic 14-methyl sterol intermediate induced by ketoconazole by showing that amastigotes are re-sensitized by addition of upstream metabolites of CYP51 (like FPP). However, the phenotype of the mGDH-deficient T. cruzi amastigotes does not support the hypothesis that increased glutamate flux is responsible for sensitization to ketoconazole. Specifically, one would expect that the mutant line should be more resistant to ketoconazole in the presence of glutamine, which is not observed. The authors should reconcile these results with their model. It was noted that T. cruzi may express another active GDH which could compensate for loss of the deleted GDH, or alternatively that the GDH reaction might be by-passed by transaminase reactions. Further experiments may be needed to define the role of these GDH enzymes in ketoconazole sensitivity (including testing the effect of GDH overexpression if effective inhibition of glutamate catabolism is not possible), or these data removed from the manuscript. Along the same lines, further discussion on the phenotype of the cIDH mutant (what was expected and what was observed) is warranted.</p></disp-quote><p>Data for the ΔmGDH <italic>T. cruzi</italic> mutants was included in the original manuscript to illustrate the connection between parasite glutamine metabolism (as opposed to host) and the mechanism of amastigote protection from azole-mediated death in the absence of glutamine. However, we agree with the reviewers that the specific nature of this interaction is not yet understood and we have removed this data. We will continue to pursue investigation regarding how the parasite metabolizes glutamine and the implications for protection from azoles.</p><disp-quote content-type="editor-comment"><p>2) Further explanation of the 13C-glutamine labelling experiments is needed (Figure 3B). The major sterol isotopomers detected in the GC-MS analyses contain +1 and +2 13C-atoms. One would expect +2 or higher isotopomers (i.e. +4, +6 etc) if glutamine is used to synthesize acetyl-CoA via citrate (either by oxidative or reductive pathways). How do the authors reconcile the observed labelling of the sterols and/or have they considered whether fatty acid b-oxidation might also be contributing to elevated acetyl-CoA and sterol synthesis under glucose limiting conditions ?</p></disp-quote><p>We agree that if glutamine is incorporated into parasite sterols by similar mechanisms to other systems the +C numbers should be higher than we observe. It is likely that the parasite is using a non-canonical and yet undescribed pathway for this process and the potential role of FA b-oxidation in conditions of nutrient restriction is something we will consider in future. For the 13C analysis the parasites are in glucose, glutamine and FBS (2%) replete conditions. It is possible that in glutamine deplete conditions other metabolic process are altered and indirectly changing the dynamics of sterol synthesis important for the phenotypes we observe. One example of how these possibilities have re-framed the context of these presented data is shown in the sixth paragraph of the Discussion.</p><disp-quote content-type="editor-comment"><p>3) The evidence for the accumulation of 14-methylated sterol intermediates after ketoconazole treatment is not clear (Figure 3). Specifically, the authors should address the following issues.</p><p>• Is there any verification to show amastigote purity?</p></disp-quote><p>1) We have previously used electron microscopy and western blot for specific host organelles to assess the purity of out isolated amastigote preparations (PMID: 29281741). This is now reflected more clearly in the revised manuscript (subsection “Glutamine-derived carbons are incorporated into amastigote sterols”).</p><p>2) Additionally, we analyzed preparation of uninfected cultures for GC-MS to measure purify of our sterol preparations. When uninfected host cells were prepared alongside infected cultures, sterols (e.g. lanosterol, isomers of ergosterol) associated with amastigotes sterol synthesis were not detectable by GC-MS. Trace amounts (&lt;1%) of host derived cholesterol were detectable in preparations from uninfected cultures.</p><disp-quote content-type="editor-comment"><p>• Figure 3A: the TLC shows a loss of ergosterol/ergosterol isomer after ketoconazole treatment but no accumulation of CYP51 substrates is detected. Is the loading equal?</p></disp-quote><p>The loading in Figure 3A is not equal (D2: 4.7e7 and D2+ketoconazole: 2.1e7 amastigotes per lane). Additionally, we cannot control for variable extraction efficiencies prior to analysis by TLC, Figure 3A. We also cannot say that the band running at the same height as the lanosterol standard is composed of a single or multiple species. Therefore, we cannot definitively show accumulation of lanosterol/eburicol with Figure 3A alone. As a result, for clarity we have removed the TLC since the same conclusions can be made, but more precisely with the 13C data alone.</p><disp-quote content-type="editor-comment"><p>• Figure 3B: it seems that cholesterol is the most abundance sterol species in amastigotes based on natural sterol %, but it is not consistent with Figure 3C.</p></disp-quote><p>Cholesterol is the major sterol species in Figure 3A and Figure 3C (Figure 2A, B in updated version). In Figure 3C (now Figure 2A) the major peak (RT 12.98) is the ISTD that is used to normalize between samples. The “natural sterol %” is a metric that reports the percentage within a given species that have 13C incorporation. In this case the % for cholesterol in Figure 3B (revised Figure 2B) reflects that no 13C is detected in cholesterol, not that it is the most predominant species in the sample. It should also be reiterated that the biological (ISTD normalized) variability we see in cholesterol is higher than in amastigote sterols (see modified Figure 2—figure supplement 2) and consequently we cannot confidently quantify cholesterol associated with isolated intracellular amastigotes but we can determine that no 13C is incorporated into the cholesterol that is detectable.</p><disp-quote content-type="editor-comment"><p>• Resolution for Figure 3B-C is insufficient.</p></disp-quote><p>The data in this figure has been enlarged and saved at a higher resolution. In the modified manuscript these data can be found in Figure 2.</p><disp-quote content-type="editor-comment"><p>• Figure 3C: what is the most dominant peak at 12.8-13.0 in all samples? Is it lanosterol or ergosterol isomer?</p></disp-quote><p>In untreated (without ketoconazole) the dominant peak normalized to the ISTD is lanosterol (RT 13.04).</p><disp-quote content-type="editor-comment"><p>4) Figure 4: while the presented data is compelling, evidence is missing that these isoprenoid precursors are indeed affecting sterol production, rather than acting via a tertiary mechanism. Such evidence should be provided, or conclusions in text tempered.</p></disp-quote><p>We agree that this evidence does not directly show that isoprenoid precursors are directly incorporated into sterols. We have added statements to the text (Discussion) that reflect this reality.</p><p>We have included new data using BPTES, a small molecule inhibitor of human glutaminase GLS1, that was used to block the conversion of glutamine to glutamate in the host cell. BPTES does not inhibit the ability of isolated <italic>T. cruzi</italic>amastigotes to utilize glutamine for respiration (Figure 3—figure supplement 1A) indicating specificity for host glutaminase. We show that BPTES treatment of infected cells increased the incorporation of 13C-glutamine into amastigote sterols and resulted in an overall increase in amastigote sterol abundance (Figure 3). This result is consistent with a mechanism of increased glutamine availability for the intracellular parasite when glutamine metabolism was blocked in the host cell. Importantly, BPTES treatment also sensitized amastigotes to ketoconazole in the absence of supplemental glutamine, suggesting a correlation between flux into the sterol synthesis pathway and azole sensitivity. However, we cannot rule out additional glutamine fueled pathways in this process as acknowledged in the text (Discussion).</p><p>We are also unable to address the influence of host cholesterol scavenging and how this process may influence endogenous sterol synthesis in the parasite (Discussion).</p><p>We have also modified the text throughout to temper the conclusions.</p></body></sub-article></article>